BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
anaplastic oligodendrogliomas 2005:2010[pubdate] *count=100
270 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
anaplastic oligodendrogliomas
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 270
1.
Thal D, Xavier CP, Rosentreter A, Linder S, Friedrichs B, Waha A, Pietsch T, Stumpf M, Noegel A, Clemen C:
Expression of coronin-3 (coronin-1C) in diffuse gliomas is related to malignancy.
J Pathol
; 2008 Mar;214(4):415-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here, we present for the first time a detailed analysis of the expression pattern of coronin-3 in human brain tumours and demonstrate that coronin-3 expression correlates with
malignant
phenotype in diffuse gliomas.
High-
grade
gliomas, such as
anaplastic
astrocytomas,
anaplastic oligodendrogliomas
,
anaplastic
oligoastrocytomas and glioblastomas, show high numbers of tumour cells positive for coronin-3, while diffuse low-
grade
gliomas, such as diffuse astrocytomas,
oligodendrogliomas
and oligoastrocytomas, exhibit low numbers of coronin-3-positive tumour cells.
In order to explore and verify a contribution of coronin-3 to the
malignant
phenotype of diffuse gliomas, we employed an efficient shRNA-mediated coronin-3 knockdown in U373 and A172 human glioblastoma cells.
Together, our findings demonstrate evidence for a contribution of coronin-3 expression in the
malignant
progression of diffuse gliomas.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Microfilament Proteins / metabolism
[MeSH-minor]
Astrocytes / metabolism. Cell Movement. Cell Proliferation. Extracellular Matrix / pathology. Humans. Matrix Metalloproteinases / metabolism.
Neoplasm
Invasiveness.
Neoplasm
Proteins / deficiency.
Neoplasm
Proteins / genetics.
Neoplasm
Proteins / metabolism.
Neoplasm
Proteins / physiology.
Tumor
Cells, Cultured
MedlinePlus Health Information.
consumer health - Brain Tumors
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18189330.001).
[ISSN]
0022-3417
[Journal-full-title]
The Journal of pathology
[ISO-abbreviation]
J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 145420-64-0 / coronin proteins; EC 3.4.24.- / Matrix Metalloproteinases
2.
Oshiro S, Komatsu F, Tsugu H, Nabeshima K, Abe H, Ohkawa M, Inoue T:
[A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination].
No Shinkei Geka
; 2010 Mar;38(3):279-85
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case of intramedullary cervical metastasis from cerebellar
anaplastic
oligodendroglioma
without typical MR appearance for CSF dissemination].
We report a case of intramedullary cervical metastasis from cerebellar
anaplastic
oligodendroglioma
without any MR appearance for CSF dissemination or recurrence in the primary
tumor
site.
The case was a 73-year-old female
who
underwent
tumor
resection for cerebellar
anaplastic
oligodendroglioma
following irradiation and TMZ chemotherapy.
The histological examination obtained in spinal surgery revealed evidence of similar features consistent with a previous cerebellar
tumor
with
anaplastic
oligodendroglioma
.
Although CSF dissemination by
malignant
glioma with leptomeningeal enhancement is relatively well recognized at their terminal stage, cases with intramedullary cervical metastasis without any leptomeningeal enhancement have only been rarely described.
We discussed the mechanisms of intramedullary cervical metastasis from intracranial
malignant
glioma.
[MeSH-major]
Cerebellar Neoplasms / pathology.
Oligodendroglioma
/ pathology. Spinal Cord Neoplasms / secondary
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20229774.001).
[ISSN]
0301-2603
[Journal-full-title]
No shinkei geka. Neurological surgery
[ISO-abbreviation]
No Shinkei Geka
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
3.
Gupta M, Djalilvand A, Brat DJ:
Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Am J Clin Pathol
; 2005 Nov;124(5):755-68
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clarifying the diffuse gliomas: an update on the
morphologic
features and markers that discriminate
oligodendroglioma
from astrocytoma.
Diffuse gliomas are the most common brain tumors and include astrocytomas,
oligodendrogliomas
, and oligoastrocytomas.
Their correct pathologic
diagnosis
requires the ability to distinguish astrocytic from
oligodendroglial
differentiation in histologic sections, a challenging feat even for the most experienced neuropathologist.
Interobserver variability in the
diagnosis
of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping
morphologic
features, and variations in training and practice among pathologists.
A select, albeit imperfect, group of molecular and immunohistochemical tests are available to assist in
diagnosis
of these lesions.
Combined loss of chromosomes 1p and 19q is a genetic signature of
oligodendrogliomas
, whereas gains of chromosome 7 in the setting of intact 1p/19q are more typical of astrocytomas.
Detection of amplified epidermal growth factor receptor favors the
diagnosis
of high-
grade
astrocytomas over
anaplastic
oligodendroglioma
, which is especially relevant for small cell astrocytomas.
Strong nuclear staining for p53 often reflects TP53 mutation and is typical of low-
grade
astrocytomas.
[MeSH-major]
Astrocytoma / pathology. Brain Neoplasms / pathology.
Oligodendroglioma
/ pathology
[MeSH-minor]
Biomarkers,
Tumor
. Genes, p53. Genetic Markers. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Mutation. Receptor, Epidermal Growth Factor / genetics
Genetic Alliance.
consumer health - Diffuse Astrocytoma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16203285.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Glial Fibrillary Acidic Protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
Advertisement
4.
Ohgaki H, Kleihues P:
Genetic alterations and signaling pathways in the evolution of gliomas.
Cancer Sci
; 2009 Dec;100(12):2235-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Most frequent and
malignant
are glioblastomas.
The vast majority (>90%) develops rapidly after a short clinical history and without evidence of a less
malignant
precursor lesion (primary or de novo glioblastoma).
Secondary glioblastomas develop more slowly through progression from low-
grade
or
anaplastic
astrocytoma.
Recently, isocitrate dehydrogenase 1 (IDH1) mutations have been identified as a very early and frequent genetic alteration in the pathway to secondary glioblastomas as well as that in
oligodendroglial
tumors, providing the first evidence that low-
grade
astrocytomas and
oligodendrogliomas
may share common cells of origin.
In this review, we summarize the current status of genetic alterations and signaling pathways operative in the evolution of astrocytic and
oligodendroglial
tumors.
[MeSH-minor]
Animals. Cyclin-Dependent Kinase Inhibitor p16 / physiology. Gene Expression Profiling. Humans. Isocitrate Dehydrogenase / physiology. Loss of Heterozygosity. PTEN Phosphohydrolase / physiology. Phosphatidylinositol 3-Kinases / physiology.
Tumor
Suppressor Protein p14ARF / physiology.
Tumor
Suppressor Protein p53 / physiology
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19737147.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.67 / PTEN Phosphohydrolase
[Number-of-references]
92
5.
Pipp I, Wagner L, Rössler K, Budka H, Preusser M:
Secretagogin expression in tumours of the human brain and its coverings.
APMIS
; 2007 Apr;115(4):319-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We found focal or widespread secretagogin expression in tumour cells in 1/18 oligoastrocytomas, 1/19
oligodendrogliomas
, 2/20
anaplastic oligodendrogliomas
, 2/9 ependymomas, 2/11
anaplastic
ependymomas, 2/10 glioblastomas, 3/11 gangliogliomas and 1/2
anaplastic
gangliogliomas, 10/10 central neurocytomas, 5/10 classic medulloblastomas, 4/5 desmoplastic medulloblastomas, 3/5 large cell/
anaplastic
medulloblastomas, 3/5 neuroblastomas, 3/10 meningiomas, 2/10 haemangioblastomas, and 13/19 pituitary adenomas.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms /
diagnosis
. Calcium-Binding Proteins / analysis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17504298.001).
[ISSN]
0903-4641
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / SCGN protein, human; 0 / Secretagogins
6.
Brandsma D, van den Bent MJ:
Molecular targeted therapies and chemotherapy in malignant gliomas.
Curr Opin Oncol
; 2007 Nov;19(6):598-605
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular targeted therapies and chemotherapy in
malignant
gliomas.
PURPOSE OF REVIEW: To review current developments in the field of chemotherapy and targeted treatment of high-
grade
glioma.
RECENT FINDINGS: Two independent large phase
III
trials on adjuvant procarbazine, lomustine and vincristine chemotherapy in
anaplastic
oligodendroglial
tumors have shown this improves progression-free survival, but not overall survival, regardless of 1p/19q status.
If given sequentially, the timing of procarbazine, lomustine and vincristine chemotherapy has no clear effect on the survival of
anaplastic
oligodendroglioma
.
Virtually none of the many new targeted agents directed against pathways that are upregulated in high-
grade
gliomas has shown significant clinical activity as single agent in phase II studies.
The role of combined chemo-irradiation for non-glioblastoma multiforme high-
grade
glioma remains to be identified.
[MeSH-minor]
Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Humans. Medical Oncology / methods. Models, Biological.
Neoplasm
Metastasis.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ genetics. Signal Transduction. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DACARBAZINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17906459.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
[Number-of-references]
74
7.
Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE:
Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
Clin Neuropathol
; 2005 Sep-Oct;24(5):225-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Challenging
diagnosis
:
oligodendroglioma
versus extraventricular neurocytoma.
Diagnosis
of
oligodendroglioma
from other clear cell neoplasms of central nervous system (
CNS
) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
Herein, we present a 44-year-old male patient
who
had
a diagnosis
of right parietal
oligodendroglioma grade
II in 1994 which recurred in 2002.
He presented with intratumoral hemorrhage and he underwent radical resection of
tumor
in 2003.
Histopathological examination of the recurrent
tumor
showed
anaplastic
progression with confusing immunohistochemical (IHC) results; the
tumor
was positive for NeuN and synaptophysin staining.
The question arisen was whether the recurrent
tumor
was an
oligodendroglioma
with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as
oligodendroglioma
.
Chromosomal analysis revealed 1p/19q deletion, which led to the
diagnosis
ofanaplastic
oligodendroglioma grade III
.
Accurate
diagnosis
of
oligodendroglioma
is crucial due to recent advances and promises in its treatment.
Current diagnostic methods of
oligodendroglial
tumors are discussed in context of differentiating
oligodendrogliomas
from other clear cell neoplasms of
CNS
, especially from extraventricular neurocytomas.
[MeSH-major]
Brain Neoplasms / pathology.
Neoplasm
Recurrence, Local / pathology. Neurocytoma / pathology.
Oligodendroglioma
/ pathology
[MeSH-minor]
Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics.
Diagnosis
, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16167546.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Nerve Tissue Proteins; 0 / Synaptophysin
8.
Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G:
Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works.
J Med Imaging Radiat Oncol
; 2009 Jun;53(3):305-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Retrospective review of prognostic factors, including 1p19q deletion, in low-
grade
oligodendrogliomas
and a review of recent published works.
The purpose of the present study was to investigate potential prognostic factors in low-
grade
oligodendrogliomas
(LGOs), particularly 1p19q deletion, due to its proven prognostic significance in
anaplastic oligodendrogliomas
.
We carried out a retrospective review of patients with a histological
diagnosis
of LGO between 1990 and 2000 in Auckland and Wellington, New Zealand.
Univariate analysis of potential prognostic factors including 1p19q status, age, tumour size, tumour crossing midline, tumour enhancement, extent of surgery and seizures at
diagnosis
was carried out.
[MeSH-major]
Brain Neoplasms.
Oligodendroglioma
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19624298.001).
[ISSN]
1754-9485
[Journal-full-title]
Journal of medical imaging and radiation oncology
[ISO-abbreviation]
J Med Imaging Radiat Oncol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Australia
[Number-of-references]
30
9.
Katoh Y, Katoh M:
Comparative genomics on SLIT1, SLIT2, and SLIT3 orthologs.
Oncol Rep
; 2005 Nov;14(5):1351-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
SLIT1 mRNA was expressed in fetal brain, infant brain,
anaplastic
oligodendroglioma
, and Jurkat T cells.
SLIT2 and SLIT3 mRNAs were co-expressed in embryonic stem (ES) cells with embryoid body formation, and diffuse
type
gastric cancer with signet ring cell features.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16211308.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / SLIT1 protein, human; 0 / SLIT3 protein, human; 0 / Slit homolog 2 protein; 0 / Slit3 protein, mouse; 0 / Slit3 protein, rat
10.
da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T:
Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
Arch Immunol Ther Exp (Warsz)
; 2008 Jul-Aug;56(4):267-76
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Malignant
gliomas commonly overexpress the oncogenes EGFR and PDGFR and contain mutations and deletions of the
tumor
suppressor genes PTEN and TP53.
MATERIALS AND METHODS: Applying this method, a phase I/II clinical trial of POH was performed in patients with relapsed
malignant
gliomas after standard treatment: surgery, radiotherapy, and chemotherapy.
The cohort consisted of 37 patients, including 29 with glioblastoma multiforme (GBM), 5 with
grade III
astrocytoma (AA), and 3 with
anaplastic
oligodendroglioma
(AO).
Complete response was defined as neurological stability or improvement of conditions, disappearance of CT/MRI
tumor
image, and corticosteroid withdraw; partial response (PR) as > or =50 reduction of CT/MRI
tumor
image, neurological stability, or improvement of conditions and corticosteroid requirement; progressive course (PC) as > or =25 increase in CT/MRI
tumor
image or the appearance of a new lesion; and stable disease as a lack of any changes in the CT/MR
tumor
image or neurological status.
There were no toxicity events and the regression of
tumor
size in some patients is suggestive of antitumor activity.
[MeSH-minor]
Administration, Intranasal. Adult. Aged. Apoptosis / drug effects. Astrocytoma / drug therapy. Astrocytoma / metabolism. Disease-Free Survival. Female. Glioblastoma / drug therapy. Glioblastoma / metabolism. Humans. Male. Middle Aged.
Neoplasm
Recurrence, Local / drug therapy.
Neoplasm
Recurrence, Local / metabolism.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ metabolism. Signal Transduction / drug effects
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Cancer Res Clin Oncol. 2001 Feb;127(2):91-5
[
11216919.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4425-31
[
11389071.001
]
[Cites]
J Neurosurg. 2002 Mar;96(3):559-64
[
11892633.001
]
[Cites]
Int J Mol Med. 2002 Dec;10(6):785-8
[
12430008.001
]
[Cites]
Mol Carcinog. 2003 Jan;36(1):6-14
[
12503074.001
]
[Cites]
Brain Pathol. 2003 Jan;13(1):52-61
[
12580545.001
]
[Cites]
J Lipid Res. 2003 Jun;44(6):1209-15
[
12671036.001
]
[Cites]
Anticancer Drugs. 2004 Jun;15(5):513-23
[
15166627.001
]
[Cites]
Exp Biol Med (Maywood). 2004 Jul;229(7):567-85
[
15229351.001
]
[Cites]
Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76
[
15205914.001
]
[Cites]
Mol Carcinog. 2004 Sep;41(1):39-53
[
15352124.001
]
[Cites]
Anticancer Res. 1998 Mar-Apr;18(2A):823-8
[
9615726.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1678-86
[
15753362.001
]
[Cites]
Oncol Rep. 2005 May;13(5):943-7
[
15809762.001
]
[Cites]
Surg Neurol. 2006;65 Suppl 1:S1:2-1:8; discussion S1:8-1:9
[
16427438.001
]
[Cites]
Clin Cancer Res. 2006 Jul 1;12(13):3882-9
[
16818682.001
]
[Cites]
Surg Neurol. 2006 Dec;66(6):611-5
[
17145324.001
]
[Cites]
Cancer Res. 2007 Mar 1;67(5):2098-106
[
17332339.001
]
[Cites]
Brain Pathol. 2007 Jul;17(3):319-24
[
17598825.001
]
[Cites]
Nat Rev Drug Discov. 2007 Jul;6(7):541-55
[
17585331.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):121-33
[
17588166.001
]
[Cites]
Cancer Invest. 2007 Sep;25(6):484-94
[
17882662.001
]
[Cites]
Cell Mol Life Sci. 2007 Oct;64(19-20):2575-89
[
17628742.001
]
[Cites]
Neurocirugia (Astur). 2007 Oct;18(5):373-82
[
18008011.001
]
[Cites]
Eur J Neurosci. 2007 Dec;26(11):3261-6
[
18005061.001
]
[Cites]
Cancer Invest. 2008 Apr-May;26(3):269-77
[
18317968.001
]
[Cites]
Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57
[
17885756.001
]
[Cites]
Biochem Pharmacol. 2004 Nov 1;68(9):1739-47
[
15450939.001
]
[Cites]
Oncogene. 1997 Dec 4;15(23):2755-65
[
9419966.001
]
(PMID = 18726148.001).
[ISSN]
0004-069X
[Journal-full-title]
Archivum immunologiae et therapiae experimentalis
[ISO-abbreviation]
Arch. Immunol. Ther. Exp. (Warsz.)
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Monoterpenes; 319R5C7293 / perilla alcohol; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.6.5.2 / ras Proteins
[Other-IDs]
NLM/ PMC2778682
11.
Maiuri F, Del Basso De Caro M, Siciliano A, Peca C, Vergara P, Mariniello G, Pettinato G:
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Clin Neuropathol
; 2010 Mar-Apr;29(2):109-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of growth factors in brain tumors: correlation with
tumor grade
, recurrence and survival.
OBJECTIVE: The aim of this study is to evaluate the correlation between the expression of some growth factors (GFs) and the
tumor grade
, recurrence and survival of brain glial and ependymal tumors.
MATERIAL AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tenascine, transforming growth factor (TGFbeta), isomeres, platelet-derived growth factor (PDGF) and p53 was studied in 40 primary brain tumors, both low-
grade
and high-
grade
, including astrocytomas,
oligodendrogliomas
, glioblastomas and ependymomas.
The positivity and intensity of the immunohistochemical expression were correlated with the
tumor grade
, the interval and
type
of recurrence, and the survival.
RESULTS: The expression of all GFs, excepting TGFbeta1, TGFbetaRI and tenascine, was found to be correlated with the
tumor grade
in all tumors of both astroglial and
oligodendroglial
origin, whereas ependymomas showed significant differences only for EGFR.
Low-
grade
(
Grade
II) tumors recurring as
anaplastic
(
Grade III
) forms showed GF expression rather similar to initially high-
grade
gliomas and significantly higher than that of low-
grade
(
Grade
II) tumors in both initial surgery and recurrence.
Besides, low-
grade
(
Grade
II) tumors recurring as low-
grade
showed significantly longer median recurrence time (5.4 vs. 3.5 years) and better median survival (8.3 vs. 5.4 years) than those recurring as
anaplastic
forms (
WHO III
).
CONCLUSION: The immunohistochemical study of expression of VEGF, EGFR, TGFbeta2, TGFbeta3, PDGF and p53 in all low-
grade
(
Grade
II) brain gliomas at the first operation may help to differentiate cases with slower evolution and longer survival from those with higher potential of
anaplastic
transformation.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis
[MeSH-minor]
Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged.
Neoplasm
Recurrence, Local / metabolism. Prognosis. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20175962.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins
12.
Roldán G, Scott J, George D, Parney I, Easaw J, Cairncross G, Forsyth P, Yan E:
Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.
Can J Neurol Sci
; 2008 May;35(2):204-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leptomeningeal disease from
oligodendroglioma
: clinical and molecular analysis.
BACKGROUND: Leptomeningeal disease (LMD) is a late complication of
malignant
glioma, mostly of glioblastoma, that usually responds poorly to treatment and is rapidly fatal.
A long surviving case led us to review our experience with LMD in patients with
oligodendrogliomas
.
Patients with both
oligodendroglial
tumors and LMD were identified.
RESULTS: Seven out of 145 patients with
oligodendroglioma
were diagnosed with LMD.
Median age at
tumor diagnosis
was 41 years (range, 28-50).
None had radiographic or pathological evidence of leptomeningeal or subependymal
tumor
at initial
diagnosis
.
Most patients had pure
anaplastic oligodendrogliomas
(4/7); 6/7 had 1p/19q co-deletion.
The median time to LMD was 76 months (range, 19-151) from initial
diagnosis
and 28 months (range, 0-36) from first relapse, respectively.
The median survival from initial
diagnosis
was 104 months (range, 19-183) and from LMD
diagnosis
was 32 months (range, 2-43).
CONCLUSIONS: Leptomeningeal disease is a complication of
oligodendroglioma
that may occur preferentially in long surviving patients with 1p/19q co-deletion.
Leptomeningeal disease in patients with
oligodendrogliomas
appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.
[MeSH-major]
Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Meningeal Neoplasms / genetics. Meninges / pathology.
Oligodendroglioma
/ genetics
Genetic Alliance.
consumer health - Oligodendroglioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18574935.001).
[ISSN]
0317-1671
[Journal-full-title]
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
[ISO-abbreviation]
Can J Neurol Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Canada
13.
Gaughen JR, Bourne TD, Aregawi D, Shah LM, Schiff D:
Focal neuronal gigantism: a rare complication of therapeutic radiation.
AJNR Am J Neuroradiol
; 2009 Nov;30(10):1933-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We report this rare delayed complication in a patient following treatment of a right frontal
anaplastic
oligodendroglioma
.
[MeSH-major]
Brain Neoplasms / radiotherapy. Frontal Lobe / pathology.
Oligodendroglioma
/ radiotherapy. Radiation Injuries / pathology. Radiotherapy / adverse effects
Genetic Alliance.
consumer health - Gigantism
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19574493.001).
[ISSN]
1936-959X
[Journal-full-title]
AJNR. American journal of neuroradiology
[ISO-abbreviation]
AJNR Am J Neuroradiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
14.
McLendon RE, Herndon JE 2nd, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD:
Survival analysis of presumptive prognostic markers among oligodendrogliomas.
Cancer
; 2005 Oct 15;104(8):1693-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival analysis of presumptive prognostic markers among
oligodendrogliomas
.
BACKGROUND: Allelic losses of 1p and 19q arms correlate with the
oligodendroglial
phenotype as well as with sensitivity to radiotherapy and chemotherapy.
Furthermore, the DNA repair gene, methylguanine methyltransferase (MGMT), is diminished in 80% of
oligodendroglial
tumors and represents a possible mechanism for this therapeutic sensitivity.
However, the authors questioned the relevance of genetic testing and measuring MGMT levels in tumors that were diagnostic of
oligodendroglioma
.
METHODS: The authors performed a retrospective analysis of 1p, 19q, 9p21, TP53, and MGMT status in 46 patients with
oligodendrogliomas
to address any relations that may exist among these markers with regard to progression-free survival (PFS) and total survival.
RESULTS: The authors found that survival among patients with light microscopically diagnosed
oligodendroglial
tumors demonstrating LOH of 1p and 19q trended toward statistical significance (P = 0.102 and P = 0.058, respectively).
9p21 LOH was significant as a predictor of PFS only among
anaplastic oligodendrogliomas
in this cohort (P = 0.033).
Low-level MGMT labeling index (LI) (< 20%) was noted in 86% of all
oligodendroglial
tumors.
MGMT levels were decreased in a majority of
oligodendrogliomas
.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms / mortality. O(6)-Methylguanine-DNA Methyltransferase / analysis.
Oligodendroglioma
/ mortality.
Tumor
Suppressor Protein p53 / analysis
[MeSH-minor]
Chromosomes, Human / genetics. Cohort Studies. Disease-Free Survival. Humans. In Situ Hybridization. Loss of Heterozygosity.
Neoplasm
Proteins. Prognosis. Retrospective Studies. Survival Rate
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 American Cancer Society
(PMID = 16116609.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 1P50 CA108786; United States / NCI NIH HHS / CA / 5R01 CA43722
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
15.
Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C:
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Int J Radiat Oncol Biol Phys
; 2005 Oct 1;63(2):511-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reirradiation of recurrent high-
grade
gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross
tumor
volume for stereotactic fractionated radiotherapy.
PURPOSE: To develop a valid treatment strategy for recurrent high-
grade
gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide.
PATIENTS AND METHODS: The trial included a total of 44 patients with recurrent high-
grade
gliomas (1 patient with
anaplastic
oligodendroglioma
, 8 with
anaplastic
astrocytoma, 33 with glioblastoma multiforme, and 2 with gliosarcoma) after previous surgery and postoperative conventional radiotherapy +/- chemotherapy.
For fractionated stereotactic radiotherapy (SFRT) treatment planning, the gross
tumor
volume was defined by (11)C-methionine positron emission tomography (MET-PET) or (123)I-alpha-methyl-tyrosine (IMT) single-photon computed emission tomography (SPECT)/computed tomography (CT)/magnetic resonance imaging (MRI) fusion in 82% of the patients and by CT/T1+gadolinium-MRI image fusion in 18% of the patients.
Median survival time were 11 months for patients
who
received SFRT based on biologic imaging plus temozolomide and significantly lower, 6 months for patients treated with SFRT without biologic imaging, without temozolomide or without both (p = 0.008, log rank).
The most important prognostic factor in univariate analysis was a long interval between initial
diagnosis
and recurrence (p = 0.0002, log-rank).
No acute neurologic toxicity
Grade
3 or higher and no
Grade
4 hematologic toxicity was observed.
CONCLUSION: This is the first study of biologic imaging optimized SFRT plus temozolomide in recurrent high-
grade
gliomas.
[MeSH-major]
Glioma / drug therapy. Glioma / radiotherapy.
Neoplasm
Recurrence, Local / drug therapy.
Neoplasm
Recurrence, Local / radiotherapy
[MeSH-minor]
Adult. Aged. Analysis of Variance. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / radionuclide imaging. Glioblastoma / radiotherapy. Gliosarcoma / drug therapy. Gliosarcoma / radionuclide imaging. Gliosarcoma / radiotherapy. Humans. Male. Methionine. Middle Aged.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ radionuclide imaging.
Oligodendroglioma
/ radiotherapy. Positron-Emission Tomography / methods. Prospective Studies. Statistics, Nonparametric. Stereotaxic Techniques. Tomography, Emission-Computed, Single-Photon / methods. alpha-Methyltyrosine
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
(L)-Methionine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16168843.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 658-48-0 / alpha-Methyltyrosine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; AE28F7PNPL / Methionine
16.
Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, Jang SJ, Lee CH, Choi JR:
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Ann Clin Lab Sci
; 2009;39(4):392-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The cases included
anaplastic
astrocytoma (4 cases),
anaplastic
oligodendroglioma
(2 cases), low
grade
astrocytoma (2 cases), low
grade oligodendroglioma
(1 case), and one case of secondary Philadelphia-positive acute lymphoblastic leukemia in a patient with glioblastoma multiforme.
Genetic Alliance.
consumer health - Glioblastoma
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
DACARBAZINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19880768.001).
[ISSN]
1550-8080
[Journal-full-title]
Annals of clinical and laboratory science
[ISO-abbreviation]
Ann. Clin. Lab. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
17.
Michotte A, Chaskis C, Sadones J, Veld PI, Neyns B:
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
J Neurol Sci
; 2009 Dec 15;287(1-2):267-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary leptomeningeal
anaplastic
oligodendroglioma
with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
Primary leptomeningeal
oligodendroglioma
occurs very rarely and in only one patient a deletion of chromosome 1p has been reported.
We describe a 60-year-old man with a prior history of an epileptic seizure three years earlier,
who
was referred because of depression and a rapid evolving cognitive impairment.
The
diagnosis
of an
anaplastic
oligodendroglioma
(
WHO grade
3) was made on pathological examination.
To our knowledge this is the first report of a patient with a primary leptomeningeal
anaplastic
oligodendroglioma
with diffuse spinal seeding bearing a 1p36/19q13 deletion.
Molecular analysis with determination of chromosome 1p/19q deletions should be performed in all cases of leptomeningeal gliomas to select those patients
who
might benefit from TMZ chemotherapy.
[MeSH-major]
Dacarbazine / analogs & derivatives. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / genetics. Mutation / genetics.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ genetics
[MeSH-minor]
Antineoplastic Agents, Alkylating / administration & dosage. Arachnoid / pathology. Brain / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Gene Deletion. Genetic Predisposition to Disease / genetics. Genotype. Humans. Magnetic Resonance Imaging. Male. Meningeal Carcinomatosis / drug therapy. Meningeal Carcinomatosis / genetics. Meningeal Carcinomatosis / pathology. Middle Aged.
Neoplasm
Metastasis / drug therapy.
Neoplasm
Metastasis / genetics.
Neoplasm
Metastasis / pathology. Pia Mater / pathology. Radiotherapy / methods. Spinal Cord / pathology. Subarachnoid Space / pathology. Treatment Outcome
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19751941.001).
[ISSN]
1878-5883
[Journal-full-title]
Journal of the neurological sciences
[ISO-abbreviation]
J. Neurol. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
18.
Horbinski C, Wang G, Wiley CA:
YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
Int J Clin Exp Pathol
; 2010 Jan 01;3(3):226-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
YKL-40 is directly produced by
tumor
cells and is inversely linked to EGFR in glioblastomas.
YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma
grade
.
Expression is higher in astrocytomas than
oligodendrogliomas
and has been reported to predict shorter survival and radiation resistance in glioblastomas (GBMs).
A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-
grade
adult glio-mas, including 28
anaplastic oligodendrogliomas
(AOs) and 51 GBMs.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuro Oncol. 1999 Jan;1(1):44-51
[
11550301.001
]
[Cites]
Oncogene. 2009 Dec 17;28(50):4456-68
[
19767768.001
]
[Cites]
N Engl J Med. 2002 Feb 7;346(6):420-7
[
11832530.001
]
[Cites]
Biochem J. 2002 Jul 1;365(Pt 1):119-26
[
12071845.001
]
[Cites]
Cancer. 2002 Jul 15;95(2):267-74
[
12124825.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4364-8
[
12154041.001
]
[Cites]
Int J Cancer. 2002 Oct 10;101(5):454-60
[
12216074.001
]
[Cites]
J Neurosurg. 2002 Dec;97(6):1397-401
[
12507139.001
]
[Cites]
Clin Cancer Res. 2003 Oct 1;9(12):4423-34
[
14555515.001
]
[Cites]
Biochem J. 2004 Jun 15;380(Pt 3):651-9
[
15015934.001
]
[Cites]
Cancer Res. 1997 Jan 15;57(2):304-9
[
9000573.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1678-86
[
15753362.001
]
[Cites]
Cancer Sci. 2005 Mar;96(3):183-90
[
15771622.001
]
[Cites]
Clin Cancer Res. 2005 Mar 15;11(6):2258-64
[
15788675.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3326-34
[
15867231.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
[
15977639.001
]
[Cites]
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8644-52
[
16361549.001
]
[Cites]
Neurosurg Focus. 2005 Nov;19(5):E2
[
16398466.001
]
[Cites]
Cancer. 2006 Mar 1;106(5):1130-9
[
16456816.001
]
[Cites]
Clin Cancer Res. 2006 Jul 1;12(13):3935-41
[
16818690.001
]
[Cites]
J Biol Chem. 2006 Oct 6;281(40):29583-96
[
16882657.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56
[
17146289.001
]
[Cites]
Gynecol Oncol. 2007 Feb;104(2):435-42
[
17023034.001
]
[Cites]
World J Surg Oncol. 2007;5:17
[
17286869.001
]
[Cites]
Clin Cancer Res. 2007 Mar 1;13(5):1429-37
[
17332285.001
]
[Cites]
J Clin Oncol. 2007 Jun 1;25(16):2288-94
[
17538175.001
]
[Cites]
Clin Cancer Res. 2007 Jun 1;13(11):3244-9
[
17545529.001
]
[Cites]
Int J Cancer. 2008 Feb 15;122(4):857-63
[
17957792.001
]
[Cites]
Urol Oncol. 2008 Jan-Feb;26(1):47-52
[
18190830.001
]
[Cites]
Eur J Haematol. 2008 Apr;80(4):310-7
[
18182077.001
]
[Cites]
Int J Cancer. 2008 May 15;122(10):2187-98
[
18092325.001
]
[Cites]
Am J Pathol. 2008 Jul;173(1):130-43
[
18556781.001
]
[Cites]
Adv Ther. 2008 Aug;25(8):801-9
[
18670741.001
]
[Cites]
FEBS Lett. 2008 Sep 22;582(21-22):3193-200
[
18708058.001
]
[Cites]
Oncogene. 2008 Nov 6;27(52):6679-89
[
18724390.001
]
[Cites]
Ann Oncol. 2009 Jan;20(1):71-7
[
18723551.001
]
[Cites]
J Clin Oncol. 2009 Feb 1;27(4):572-8
[
19075264.001
]
[Cites]
BMC Cancer. 2009;9:8
[
19134206.001
]
[Cites]
Brain Pathol. 2009 Jul;19(3):439-48
[
18652591.001
]
[Cites]
Biochem Biophys Res Commun. 2009 Oct 23;388(3):511-6
[
19666003.001
]
[Cites]
Hum Pathol. 2009 Dec;40(12):1790-7
[
19765801.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):196-201
[
11801559.001
]
(PMID = 20224722.001).
[ISSN]
1936-2625
[Journal-full-title]
International journal of clinical and experimental pathology
[ISO-abbreviation]
Int J Clin Exp Pathol
[Language]
ENG
[Grant]
United States / NIMH NIH HHS / MH / K24 MH001717; United States / PHS HHS / / K24 M401717
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ PMC2836500
[Keywords]
NOTNLM ; 10q / 1p19q / EGFR / YKL-40 / glioblastoma / oligodendroglioma
19.
Larysz D, Blamek S, Larysz P, Pietras K, Mandera M:
Posterior fossa brain tissue injury: developmental, neuropsychological, and neurological consequences of brain tumors in children.
Acta Neurochir Suppl
; 2010;106:271-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of the study was the functional neurodevelopmental assessment of children with posterior fossa tumors, specifically examining whether
tumor
location in particular cerebellar structures determines particular neuropsychological deficits.
There were 21 total and 8 subtotal resections of
tumor
, and marsupialization was performed in cases of arachnoid cysts.
Histopathological diagnoses of tumors were as follows: 4 medulloblastomas, 8 pilocytic astrocytomas, 6 fibrillary astrocytomas, 1
anaplastic
astrocytoma, 2
oligodendrogliomas
, 4
anaplastic
ependymomas, 1 choroid plexus papilloma, and 5 arachnoid cysts.
MedlinePlus Health Information.
consumer health - Neurologic Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19812963.001).
[ISSN]
0065-1419
[Journal-full-title]
Acta neurochirurgica. Supplement
[ISO-abbreviation]
Acta Neurochir. Suppl.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Austria
20.
Miwa K, Shinoda J, Yano H, Iwama T:
Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma.
AJNR Am J Neuroradiol
; 2007 Nov-Dec;28(10):2005-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relatively decreased 11C-methionine uptake within the
anaplastic
component of a mixed-
grade oligodendroglioma
.
A 56-year-old woman presented with a mixed-
grade oligodendroglioma
.
The part of the lesion with higher MET uptake was identified as an ordinary
oligodendroglioma
, whereas the part of the lesion with lower MET uptake was an
anaplastic
component of
oligodendroglioma
.
With
oligodendrogliomas
, we should be aware of the possibility that MET uptake decreases paradoxically with an increased
anaplastic
component of
oligodendroglioma
cells.
[MeSH-major]
Brain Neoplasms / radionuclide imaging. Frontal Lobe.
Oligodendroglioma
/ radionuclide imaging. Positron-Emission Tomography
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
(L)-Methionine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17905896.001).
[ISSN]
0195-6108
[Journal-full-title]
AJNR. American journal of neuroradiology
[ISO-abbreviation]
AJNR Am J Neuroradiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
21.
Kim SY, Kang HT, Choi HR, Park SC:
Reduction of Nup107 attenuates the growth factor signaling in the senescent cells.
Biochem Biophys Res Commun
; 2010 Oct 8;401(1):131-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Knockdown of Nup107 in
anaplastic
oligodendroglioma
cells caused cell death, rather than growth retardation, indicating a greater sensitivity to Nup107 depletion in cancer cells than in normal cells.
[MeSH-minor]
Active Transport, Cell Nucleus / drug effects. Animals. Cell Line,
Tumor
. Cell Proliferation. Child. Humans. Male. Mice. Mice, Inbred C57BL. Phosphorylation. Proto-Oncogene Proteins c-fos / metabolism. Signal Transduction. eIF-2 Kinase / metabolism
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20833136.001).
[ISSN]
1090-2104
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / NUP107 protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Proto-Oncogene Proteins c-fos; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.- / PERK kinase; EC 2.7.11.1 / eIF-2 Kinase
22.
Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M:
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Neuro Oncol
; 2009 Apr;11(2):167-75
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed
anaplastic oligodendrogliomas
and mixed
anaplastic
oligoastrocytomas: RTOG BR0131.
The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed
anaplastic
oligodendroglioma
(AO) and mixed
anaplastic
oligoastrocytoma (MOA).
Tumor
tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.
The worst nonhematological toxicity was
grade
4 in three patients (8%).
There were no
grade
4 nonhematological toxicities during the concurrent chemotherapy and RT.
[MeSH-major]
Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives.
Neoplasm
Recurrence, Local / therapy.
Oligodendroglioma
/ therapy
[MeSH-minor]
Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome.
Tumor
Suppressor Proteins / genetics. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Treat Rev. 1997 Jan;23(1):35-61
[
9189180.001
]
[Cites]
J Clin Oncol. 1994 Oct;12(10):2013-21
[
7931469.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Oncogene. 1999 Jul 15;18(28):4144-52
[
10435596.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
Neuro Oncol. 2007 Jul;9(3):314-8
[
17435180.001
]
[Cites]
J Neurosurg. 1996 Oct;85(4):602-7
[
8814163.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
[Cites]
Br J Cancer. 2000 Sep;83(5):588-93
[
10944597.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
[
11020580.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Clin Oncol. 2001 May 1;19(9):2449-55
[
11331324.001
]
[Cites]
Cancer Res. 2001 Jun 15;61(12):4689-92
[
11406538.001
]
[Cites]
Neurology. 2001 Jul 24;57(2):340-2
[
11468326.001
]
[Cites]
Lancet Oncol. 2001 Sep;2(9):552-60
[
11905710.001
]
[Cites]
J Neurooncol. 2003 Feb;61(3):267-73
[
12675321.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2525-8
[
12829671.001
]
[Cites]
J Neurooncol. 2003 Sep;64(3):271-8
[
14558604.001
]
[Cites]
Cancer Chemother Rep. 1966 Mar;50(3):163-70
[
5910392.001
]
[Cites]
J Neurosurg. 1985 Dec;63(6):881-9
[
4056902.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Cancer Res. 1998 Oct 1;58(19):4363-7
[
9766665.001
]
(PMID = 18779504.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
[Other-IDs]
NLM/ PMC2718988
23.
Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, Stávale JN:
MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.
AJNR Am J Neuroradiol
; 2005 Apr;26(4):777-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and
tumor grade
in nonenhancing gliomas.
BACKGROUND AND PURPOSE: Relative cerebral blood volume (rCBV) measurements derived from perfusion-weighted imaging (PWI) may be useful to evaluate angiogenesis and preoperatively estimate the
grade
of a glioma.
We hypothesized that rCBV is correlated with vascular endothelial growth factor (VEGF) expression as marker of the angiogenic stimulus in presumed supratentorial low-
grade
gliomas (LGGs).
RESULTS: Nine patients had diffuse astrocytomas (World Health Organization
grade
II), and 11 had other LGG and
anaplastic
gliomas.
In patients with heterogeneous tumors on PWI, the high-rCBV focus had areas of
oligodendroglioma
or
anaplastic
astrocytoma on stereotactic biopsy, whereas the surgical specimens were predominantly astrocytomas.
Anaplastic
gliomas had high rCBV ratios and positive VEGF immunoreactivity.
CONCLUSION: Our results confirmed the correlation among rCBV measurements, VEGF expression, and histopathologic
grade
in nonenhancing gliomas.
Its contribution in predicting
tumor
behavior and patient prognosis remains to be determined.
MedlinePlus Health Information.
consumer health - MRI Scans
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15814920.001).
[ISSN]
0195-6108
[Journal-full-title]
AJNR. American journal of neuroradiology
[ISO-abbreviation]
AJNR Am J Neuroradiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Vascular Endothelial Growth Factor A
24.
Peters M, Wohlsein P:
Anaplastic oligodendroglioma with meningeal infiltration in a free-ranging red deer (Cervus elaphus).
J Comp Pathol
; 2008 Jan;138(1):59-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
oligodendroglioma
with meningeal infiltration in a free-ranging red deer (Cervus elaphus).
This report describes an
anaplastic
oligodendroglioma
in a red deer, extending from the cerebellum and anterior medulla along the dorsal part of the brain stem to the posterior cerebral hemispheres and infiltrating the meninges.
This would appear to be the first report of an
oligodendroglioma
in a deer.
[MeSH-major]
Brain Neoplasms / veterinary. Deer. Meningeal Neoplasms / veterinary.
Oligodendroglioma
/ veterinary
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17983625.001).
[ISSN]
0021-9975
[Journal-full-title]
Journal of comparative pathology
[ISO-abbreviation]
J. Comp. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
25.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M:
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
J Clin Oncol
; 2009 Dec 10;27(35):5874-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
NOA-04 randomized phase
III
trial of sequential radiochemotherapy of
anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide.
PURPOSE: The standard of care for
anaplastic
gliomas is surgery followed by radiotherapy.
The NOA-04 phase
III
trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed
anaplastic
gliomas.
PATIENTS AND METHODS: Patients (N = 318) were randomly assigned 2:1:1 (A:B1:B2) to receive conventional radiotherapy (arm A); procarbazine, lomustine (CCNU), and vincristine (PCV; arm B1); or temozolomide (arm B2) at
diagnosis
.
Anaplastic oligodendrogliomas
and oligoastrocytomas share the same, better prognosis than
anaplastic
astrocytomas.
Hypermethylation of the O(6)-methylguanine DNA-methyltransferase (MGMT) promoter (HR = 0.59; 95% CI, 0.36 to 1.0), mutations of the isocitrate dehydrogenase (IDH1) gene (HR = 0.48; 95% CI, 0.29 to 0.77), and
oligodendroglial
histology (HR = 0.33; 95% CI, 0.2 to 0.55) reduced the risk of progression.
CONCLUSION: Initial radiotherapy or chemotherapy achieved comparable results in patients with
anaplastic
gliomas.
IDH1 mutations are a novel positive prognostic factor in
anaplastic
gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
[MeSH-minor]
Adult. Aged. Chemotherapy, Adjuvant. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Isocitrate Dehydrogenase / genetics. Kaplan-Meier Estimate. Lomustine / administration & dosage. Lomustine / adverse effects. Male. Middle Aged. Mutation. Procarbazine / administration & dosage. Procarbazine / adverse effects. Promoter Regions, Genetic. Proportional Hazards Models. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Time Factors. Treatment Failure.
Tumor
Suppressor Proteins / genetics. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2009 Dec 10;27(35):5861-2
[
19901101.001
]
[ErratumIn]
J Clin Oncol. 2010 Feb 1;28(4):708
(PMID = 19901110.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
26.
Idbaih A, Crinière E, Marie Y, Rousseau A, Mokhtari K, Kujas M, El Houfi Y, Carpentier C, Paris S, Boisselier B, Laigle-Donadey F, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY:
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.
Neuro Oncol
; 2008 Aug;10(4):540-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene amplification is a poor prognostic factor in
anaplastic oligodendrogliomas
.
Prognostic-genomic correlations testing simultaneously all these amplified genes have never been conducted in
anaplastic oligodendrogliomas
.
A set of 38 genes that have been reported to be amplified in gliomas and investigated as the main targets of amplicons were studied in a series of 52
anaplastic oligodendrogliomas
using bacterial artificial chromosome-array based comparative genomic hybridization and quantitative polymerase chain reaction.
Among the 38 target genes, 15 were found to be amplified in at least one
tumor
.
Overall, 27% of
anaplastic oligodendrogliomas
exhibited at least one gene amplification.
The most frequently amplified genes were epidermal growth factor receptor (EGFR) and cyclin-dependent kinase 4/sarcoma amplified sequence (CDK4/SAS) in 17% and 8% of
anaplastic oligodendrogliomas
, respectively.
In uni- and multivariate analyses, gene amplification was a negative prognostic factor for progression-free survival and overall survival in
anaplastic oligodendrogliomas
, providing complementary information to the classic prognostic factors identified in
anaplastic oligodendrogliomas
(extent of surgery, KPS, and chromosome arms 1p/19q status).
[MeSH-major]
Brain Neoplasms / genetics. Gene Amplification.
Oligodendroglioma
/ genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Glia. 1995 Nov;15(3):289-96
[
8586464.001
]
[Cites]
Genes Chromosomes Cancer. 1995 Jan;12(1):63-5
[
7534113.001
]
[Cites]
Cancer Res. 1996 Nov 15;56(22):5141-5
[
8912848.001
]
[Cites]
Cancer Res. 1997 Apr 1;57(7):1250-4
[
9102208.001
]
[Cites]
Hum Mol Genet. 1997 Oct;6(11):1817-22
[
9302258.001
]
[Cites]
Hum Genet. 1997 Dec;101(2):190-7
[
9402967.001
]
[Cites]
Clin Cancer Res. 1998 Jan;4(1):215-22
[
9516974.001
]
[Cites]
Oncogene. 1998 Jun 11;16(23):2997-3002
[
9662332.001
]
[Cites]
Int J Oncol. 1998 Oct;13(4):717-24
[
9735401.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Brain Pathol. 1999 Jul;9(3):435-42; discussion 432-3
[
10416984.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2318-26
[
15470710.001
]
[Cites]
Am J Clin Pathol. 2005 Jun;123(6):900-6
[
15899783.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Sep;44(1):85-96
[
15940691.001
]
[Cites]
Neuropathol Appl Neurobiol. 2005 Oct;31(5):486-90
[
16150119.001
]
[Cites]
Diagn Mol Pathol. 2005 Dec;14(4):224-9
[
16319692.001
]
[Cites]
Cancer Lett. 2006 Jan 28;232(1):79-89
[
16288831.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W477-81
[
16845053.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94
[
17021403.001
]
[Cites]
Mol Cancer. 2006;5:39
[
17002787.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
J Clin Oncol. 2006 Dec 1;24(34):5419-26
[
17135643.001
]
[Cites]
Mol Cancer Res. 2006 Dec;4(12):927-34
[
17189383.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Int J Cancer. 2008 Apr 15;122(8):1778-86
[
18076069.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Jan;42(1):68-77
[
15472895.001
]
[Cites]
Int J Oncol. 2004 Dec;25(6):1789-94
[
15547718.001
]
[Cites]
Acta Neuropathol. 2005 Mar;109(3):294-8
[
15627206.001
]
[Cites]
J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503
[
10850862.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):2162-8
[
11280781.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):868-75
[
11309335.001
]
[Cites]
Lab Invest. 2001 May;81(5):717-23
[
11351043.001
]
[Cites]
Br J Cancer. 2001 Aug 17;85(4):518-22
[
11506489.001
]
[Cites]
Glia. 2001 Oct;36(1):1-10
[
11571779.001
]
[Cites]
Int J Oncol. 2002 Jan;20(1):173-6
[
11743660.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
[
11895036.001
]
[Cites]
Int J Cancer. 2003 May 10;104(6):752-7
[
12640683.001
]
[Cites]
Brain Pathol. 2003 Oct;13(4):507-18
[
14655756.001
]
[Cites]
Brain Tumor Pathol. 2003;20(2):59-63
[
14756442.001
]
[Cites]
J Neuropathol Exp Neurol. 2004 Feb;63(2):151-8
[
14989601.001
]
[Cites]
Nat Genet. 2004 Sep;36(9):949-51
[
15286789.001
]
[Cites]
Lancet. 1985 Sep 28;2(8457):718-9
[
2863693.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Jan;83(2):470-3
[
3001737.001
]
[Cites]
Hua Xi Yi Ke Da Xue Xue Bao. 1989 Sep;20(3):243-5
[
2560457.001
]
[Cites]
Cancer Commun. 1990;2(6):201-5
[
2165797.001
]
[Cites]
Cancer Res. 1993 Jun 15;53(12):2736-9
[
8504413.001
]
[Cites]
Hum Genet. 1996 Nov;98(5):625-8
[
8882887.001
]
(PMID = 18544654.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2666226
27.
Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, Finlay J, MacDonald DR, DeAngelis LM, Cairncross JG, Oligodendroglioma Study Group:
Survey of treatment recommendations for anaplastic oligodendroglioma.
Neuro Oncol
; 2007 Jul;9(3):314-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survey of treatment recommendations for
anaplastic
oligodendroglioma
.
Anaplastic
oligodendroglioma
is
a malignant
brain
tumor
uniquely sensitive to treatment with both chemotherapy and radiotherapy.
A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO)
who
had an e-mail address listed with SNO.
Two-thirds of respondents see more than five patients with newly diagnosed
anaplastic
oligodendroglioma
annually.
The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed
anaplastic
oligodendroglioma
, treatment recommendations vary widely and are often independent of the molecular data.
[MeSH-major]
Brain Neoplasms / therapy. Molecular Biology / trends.
Oligodendroglioma
/ therapy. Practice Patterns, Physicians'
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
[Cites]
J Clin Oncol. 2006 Mar 10;24(8):1246-52
[
16525179.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62
[
11245209.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
Neurology. 2001 Oct 9;57(7):1278-81
[
11591848.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63
[
11829344.001
]
[Cites]
J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26
[
12578221.001
]
[Cites]
Ann Oncol. 2003 Apr;14(4):599-602
[
12649108.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2525-8
[
12829671.001
]
[Cites]
Ann Neurol. 1988 Apr;23(4):360-4
[
3382171.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Cancer. 2005 Oct 1;104(7):1468-77
[
16088966.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):704-10
[
15978739.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
[
11020580.001
]
(PMID = 17435180.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Other-IDs]
NLM/ PMC1907408
28.
Miller CR, Dunham CP, Scheithauer BW, Perry A:
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
J Clin Oncol
; 2006 Dec 1;24(34):5419-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Significance of necrosis in grading of
oligodendroglial
neoplasms: a clinicopathologic and genetic study of newly diagnosed high-
grade
gliomas.
PURPOSE: High-
grade
gliomas (HGGs;
WHO
grades 3-4) are highly diverse, with survival times ranging from months to years.
WHO
2000 grading criteria for high-
grade oligodendroglial
neoplasms [
anaplastic
oligoastrocytoma (AOA) and
anaplastic
oligodendroglioma
(AO)] remain subjective, and the existence of
grade
4 variants is controversial.
PATIENTS AND METHODS: Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery
type
, year of
diagnosis
, endothelial proliferation, necrosis,
oligodendroglial
histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).
In addition to patient age, the following were significant independent prognostic factors (P .001):
grade
and surgery
type
for the entire HGG cohort; modified
grade
for AOA (3 v 4); and modified
grade
, 1p/19q codeletion status, and
oligodendroglial
histology for the 586 HGGs analyzed by FISH.
[MeSH-major]
Brain Neoplasms / genetics. Brain Neoplasms / pathology.
Oligodendroglioma
/ genetics.
Oligodendroglioma
/ pathology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17135643.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / T32CA009547
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
29.
Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV:
[Immunohistochemistry in oligodendrogliomas].
Arq Neuropsiquiatr
; 2006 Mar;64(1):67-71
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Immunohistochemistry in
oligodendrogliomas
].
[Transliterated title]
Imunoistoquímica em
oligodendrogliomas
.
Oligodendrogliomas
(OL) are neuroepithelial tumors characterized by the presence of uniformly round nuclei with a clear cytoplasm around it.
Immunohistochemistry with glial and neuronal markers may be helpful in differential
diagnosis
.
Ten cases showed
anaplastic
characteristics.
The widespread staining with neuronal marker suggests central neurocytoma, but this
diagnosis
should not be done with small amount of tissue.
[MeSH-major]
Antibodies,
Neoplasm
/ analysis. Brain Neoplasms / pathology. Neuroglia / pathology.
Oligodendroglioma
/ pathology
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ immunology. Biomarkers,
Tumor
/ metabolism. Child. Child, Preschool. Humans. Immunohistochemistry. Male. Middle Aged. S100 Proteins / analysis. S100 Proteins / immunology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16622556.001).
[ISSN]
0004-282X
[Journal-full-title]
Arquivos de neuro-psiquiatria
[ISO-abbreviation]
Arq Neuropsiquiatr
[Language]
por
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Brazil
[Chemical-registry-number]
0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / S100 Proteins
30.
Blakeley J, Grossman S:
Anaplastic oligodendroglioma.
Curr Treat Options Neurol
; 2008 Jul;10(4):295-307
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
oligodendroglioma
.
Although uncommon,
anaplastic oligodendrogliomas
(AODs) are important to recognize, as they have unique molecular, histologic, and clinical features.
If the MRI suggests
a malignant
glioma, maximal feasible
tumor
resection is advised for accurate
diagnosis
and for relief of
tumor
-related neurologic symptoms.
Tumor
responses to PCV (the combination of procarbazine, lomustine, and vincristine) and to temozolomide have been documented in patients with AODs.
The recognition that 1p19q codeletion is a marker of
oligodendroglial
differentiation and the subsequent prospective confirmation of this marker's importance in predicting better prognosis have been critical discoveries.
Tumors with intermediate
oligodendroglial
features or mixed astrocytic features should be referred for 1p19q assessment.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18579016.001).
[ISSN]
1092-8480
[Journal-full-title]
Current treatment options in neurology
[ISO-abbreviation]
Curr Treat Options Neurol
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA006973
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS567597; NLM/ PMC3994534
31.
Cartalat-Carel S, Chinot O, Honnorat J:
[Place of chemotherapy and radiotherapy in the management of oligodendrogliomas].
Neurochirurgie
; 2005 Sep;51(3-4 Pt 2):379-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Place of chemotherapy and radiotherapy in the management of
oligodendrogliomas
].
Twenty years ago, the discovery of the chemosensitivity of
anaplastic oligodendrogliomas
considerably boosted interest for these tumors.
In spite of difficulties for histological
diagnosis
, numerous studies on radiotherapy and chemotherapy for
oligodendrogliomas
appeared these last years.
For low
grade
oligodendrogliomas
, radiotherapy delays the
anaplastic
transformation, but does not modify the overall survival; its indication has to be discussed particularly in the absence of clinical symptoms.
Chemotherapy seems to be effective for low
grade
oligodendrogliomas
as well as
anaplastic
tumors.
However, phase
III
studies are necessary to clarify the contribution of chemotherapy for the treatment of low
grade
oligodendrogliomas
, mainly in relation to radiotherapy.
In
anaplastic oligodendrogliomas
, in spite of the lack of phase
III
studies, radiotherapy seems to be effective.
[MeSH-major]
Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ radiotherapy
[MeSH-minor]
Combined Modality Therapy. Humans.
Neoplasm
Staging. Survival Rate
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16292180.001).
[ISSN]
0028-3770
[Journal-full-title]
Neuro-Chirurgie
[ISO-abbreviation]
Neurochirurgie
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
55
32.
Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ:
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Neuro Oncol
; 2009 Dec;11(6):737-46
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular analysis of
anaplastic
oligodendroglial
tumors in a prospective randomized study: A report from EORTC study 26951.
Recent studies have shown that the clinical outcome of
anaplastic
oligodendroglial
tumors is variable, but also that the histological
diagnosis
is subject to interobserver variation.
We investigated whether the assessment of 1p/19q codeletion, polysomy of chromosome 7, epidermal growth factor receptor (EGFR) gene amplification (EGFR(amp)), and loss of chromosome 10 or 10q offers additional prognostic information to the histological
diagnosis
and would allow molecular subtyping.
For this study, we used the clinical data and
tumor
samples of the patients included in multicenter prospective phase
III
European Organisation for Research and Treatment of Cancer (EORTC) study 26951 on the effects of adjuvant procarbazine, chloroethyl cyclohexylnitrosourea (lomustine), and vincristine chemotherapy in
anaplastic
oligodendroglial
tumors.
Three different analyses were performed: on all included patients based on local pathology
diagnosis
, on the patients with confirmed
anaplastic
oligodendroglial
tumors on central pathology review, and on this latter group but after excluding
anaplastic
oligoastrocytoma (AOA) with necrosis.
As a reference set for glioblastoma multiforme (GBM), patients from the prospective randomized phase
III
study on GBM (EORTC 26981) were used as a benchmark.
In 257 of 368 patients, central pathology review confirmed the presence of an
anaplastic
oligodendroglial tumor
.
Tumors with combined 1p and 19q loss (1p(loss)19q(loss)) were histopathologically diagnosed as
anaplastic
oligodendroglioma
, were more frequently located in the frontal lobe, and had a better outcome.
Anaplastic
oligodendroglial
tumors with EGFR(amp) were more frequently AOA, were more often localized outside the frontal lobe, and had a survival similar to that for GBM.
In univariate analyses, all molecular factors except loss of 10q were of prognostic significance, but on multivariate analysis a histopathological
diagnosis
of AOA, necrosis, and 1p(loss)19q(loss) remained independent prognostic factors.
AOA tumors with necrosis are to be considered
WHO grade
IV tumors (GBM).
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Genet Cytogenet. 2000 May;119(1):42-7
[
10812170.001
]
[Cites]
Neuropathology. 2008 Aug;28(4):440-3
[
18312547.001
]
[Cites]
J Pathol. 2001 May;194(1):81-7
[
11329145.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71
[
11556543.001
]
[Cites]
Cancer Res. 2001 Sep 15;61(18):6713-5
[
11559541.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104
[
11706939.001
]
[Cites]
Am J Pathol. 2002 Jul;161(1):313-9
[
12107116.001
]
[Cites]
Cancer. 2003 Mar 1;97(5):1276-84
[
12599236.001
]
[Cites]
J Clin Oncol. 1994 Oct;12(10):2013-21
[
7931469.001
]
[Cites]
Am J Pathol. 1994 Nov;145(5):1175-90
[
7977648.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Neurology. 1998 Oct;51(4):1140-5
[
9781544.001
]
[Cites]
J Neuropathol Exp Neurol. 1999 Jun;58(6):606-12
[
10374751.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2318-26
[
15470710.001
]
[Cites]
Neurology. 2004 Dec 28;63(12):2360-2
[
15623700.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):997-1003
[
15758010.001
]
[Cites]
Ann Neurol. 2005 Sep;58(3):483-7
[
16130103.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703
[
15936158.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2563-9
[
16735709.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
J Neurooncol. 2006 Oct;80(1):75-82
[
16794749.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2499-503
[
16914310.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94
[
17021403.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
J Clin Oncol. 2006 Dec 1;24(34):5419-26
[
17135643.001
]
[Cites]
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51
[
17549014.001
]
[Cites]
J Neurooncol. 2007 Sep;84(3):279-86
[
17431544.001
]
[Cites]
Oncogene. 2008 Mar 27;27(14):2097-108
[
17934521.001
]
[Cites]
Brain Pathol. 2008 Jul;18(3):360-9
[
18371182.001
]
[Cites]
Neuro Oncol. 2000 Jul;2(3):164-73
[
11302337.001
]
(PMID = 19224764.001).
[ISSN]
1523-5866
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10CA11488-25; United States / NCI NIH HHS / CA / 2U10CA11488-35
[Publication-type]
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
[Other-IDs]
NLM/ PMC2802394
33.
Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ:
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
Clin Cancer Res
; 2009 Oct 15;15(20):6430-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in
anaplastic oligodendrogliomas
with concurrent 1p/19q loss.
PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of
oligodendroglial
tumors characterized by responsiveness to chemotherapy and a favorable prognosis.
EXPERIMENTAL DESIGN: We analyzed 64
anaplastic oligodendrogliomas
with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done.
In agreement with previous studies, the group of
anaplastic oligodendrogliomas
with 1p/19q loss had significantly better progression-free survival and overall survival than
anaplastic oligodendrogliomas
with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively).
Among
anaplastic oligodendrogliomas
with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048).
CONCLUSION: The presence of polysomy in
anaplastic oligodendrogliomas
with deletion of 1p/19q is a marker of earlier recurrence.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Exp Clin Cancer Res. 1999 Sep;18(3):305-9
[
10606174.001
]
[Cites]
Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86
[
18617055.001
]
[Cites]
Genomics. 2000 Feb 15;64(1):44-50
[
10708517.001
]
[Cites]
Genes Chromosomes Cancer. 2000 Sep;29(1):16-25
[
10918389.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
[
11020580.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
Cancer Res. 2001 Sep 15;61(18):6713-5
[
11559541.001
]
[Cites]
Cancer Res. 2002 Jul 15;62(14):4100-8
[
12124348.001
]
[Cites]
J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26
[
12578221.001
]
[Cites]
Cancer. 2003 Mar 1;97(5):1276-84
[
12599236.001
]
[Cites]
J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22
[
15099021.001
]
[Cites]
Brain Pathol. 2004 Apr;14(2):121-30
[
15193024.001
]
[Cites]
Cancer Res. 1994 Sep 1;54(17):4760-3
[
8062276.001
]
[Cites]
Cancer. 1995 Nov 15;76(10):1809-13
[
8625052.001
]
[Cites]
Cancer. 1996 Sep 1;78(5):1107-13
[
8780550.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Clin Cancer Res. 2005 Feb 1;11(3):1119-28
[
15709179.001
]
[Cites]
Cancer. 2005 Feb 15;103(4):802-9
[
15637687.001
]
[Cites]
Cancer. 2005 Oct 1;104(7):1468-77
[
16088966.001
]
[Cites]
J Clin Oncol. 2006 Mar 10;24(8):1246-52
[
16525179.001
]
[Cites]
J Mol Diagn. 2006 May;8(2):268-76
[
16645215.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2499-503
[
16914310.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94
[
17021403.001
]
[Cites]
J Clin Oncol. 2006 Oct 10;24(29):4746-53
[
16954518.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
Neuro Oncol. 2007 Jul;9(3):314-8
[
17435180.001
]
[Cites]
Oncogene. 2007 Jul 26;26(34):5010-6
[
17311001.001
]
[Cites]
J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15
[
18091559.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
(PMID = 19808867.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA057683-16; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / R01 CA057683-16
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS160000; NLM/ PMC2818514
34.
Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Matsutani M, Shimizu M, Hirose T:
Anaplastic oligodendroglioma: a case report with characteristic cytologic features, including minigemistocytes.
Acta Cytol
; 2007 Jul-Aug;51(4):657-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
oligodendroglioma
: a case report with characteristic cytologic features, including minigemistocytes.
BACKGROUND: Absolute criteria for grading
oligodendrogliomas
are somewhat poorly defined in contrast to those for grading astrocytic tumors, and cytologic features of
anaplastic oligodendrogliomas
have been poorly described.
Intraoperative smears of the
tumor
showed hypercellular, loosely cohesive cell clusters and single cells with nuclear pleomorphism, numerous apoptotic cells and no discernible fibrillary processes.
Cryostat sections showed cellular nests consisting of
tumor
cells with oval nuclei and clear cytoplasm.
These cells were proliferating in the finely reticulated vascular stroma, and the
tumor
had an infiltrative margin with areas of focal necrosis and numerous calcifications.
The
diagnosis
of
anaplastic
oligodendroglioma
, World Health Organization
grade
3, was made, and the results of fluorescence in situ hybridization (chromosome 1q deletion) supported the
diagnosis
.
CONCLUSION: Intraoperative
diagnosis
of
anaplastic
oligodendroglioma
may not be easy but is possible with judicious consideration of several features: high cellularity, no fibrillary processes, nuclear atypia, pleomorphism, abundant apoptotic cells, occasional mitotic figures, coagulative necrosis, endothelial hyperplasia and characteristic conspicuous minigemistocytes.
[MeSH-major]
Brain Neoplasms / pathology.
Oligodendroglioma
/ pathology
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17718148.001).
[ISSN]
0001-5547
[Journal-full-title]
Acta cytologica
[ISO-abbreviation]
Acta Cytol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
35.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A:
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Acta Neuropathol
; 2009 Oct;118(4):469-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Type
and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial
differentiation and age: a study of 1,010 diffuse gliomas.
Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas,
oligodendrogliomas
and oligoastrocytomas of
WHO
grades II and
III
.
Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with
anaplastic
astrocytomas,
oligodendrogliomas
and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas
WHO grade
II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228
anaplastic
astrocytomas
WHO grade III
, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128
oligodendrogliomas
WHO grade
II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174
anaplastic oligodendrogliomas
WHO grade III
, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas
WHO grade
II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177
anaplastic
oligoastrocytomas
WHO grade III
.
We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the
tumor
entities.
IDH1 mutations of the R132C
type
are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in
oligodendroglial
tumors.
In addition, patients with
anaplastic
glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
[MeSH-minor]
Adult. Age Factors. Brain / pathology. Cell Differentiation. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Prognosis.
Tumor
Cells, Cultured
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19554337.001).
[ISSN]
1432-0533
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
EC 1.1.1.41 / Isocitrate Dehydrogenase
36.
Hirose Y, Yoshida K:
Chromosomal abnormalities subdivide neuroepithelial tumors into clinically relevant groups.
Keio J Med
; 2006 Jun;55(2):52-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Gliomas are the most common primary brain
tumor
, and are histopathologically classified according to their cell
type
and the degree of malignancy.
However, sometimes
diagnosis
can be controversial,and tumors of the same entity possibly have a wide range of survival.
Previous studies using comparative genomic hybridization (CGH) demonstrated that copy number aberrations(CNAs) were frequently recognized in these tumors, and revealed that a gain on chromosomal arm 7q was the most common CNA in diffuse astrocytomas, whereas a small population of the
tumor
showed losses on 1p/19q which characterizes
oligodendrogliomas
with good responsiveness to chemotherapeutic regime using procarbazine, nitrosourea and vincristine.
High
grade
(
malignant
) gliomas(i.e.
anaplastic
astrocytomas,
anaplastic oligodendrogliomas
and glioblastomas) have been reported to have a gain on 7p and losses on 9p and 10q.
[MeSH-minor]
Glioma / genetics. Glioma / pathology. Humans.
Neoplasm
Staging. Nucleic Acid Hybridization
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16823260.001).
[ISSN]
0022-9717
[Journal-full-title]
The Keio journal of medicine
[ISO-abbreviation]
Keio J Med
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Japan
[Number-of-references]
51
37.
Nafe R, Yan B, Schlote W, Schneider B:
Application of different methods for nuclear shape analysis with special reference to the differentiation of brain tumors.
Anal Quant Cytol Histol
; 2006 Apr;28(2):69-77
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
STUDY DESIGN: At least 300
tumor
cell nuclei per case were measured by means of a digital image analysis system.
(1)
oligodendrogliomas
WHO grade
II (n = 13) vs.
grade III
(n = 11), (2) medulloblastomas
WHO grade
IV (n = 14) vs.
anaplastic
ependymomas
WHO grade III
(n = 12), (3) Ki-67-positive vs. Ki-67-negative
tumor
cell nuclei in the 14 medulloblastomas.
CONCLUSION: Fourier analysis provided an optimal statistical discrimination between different brain
tumor
entities and between data sets from proliferating and nonproliferating
tumor
cell nuclei.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16637509.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
38.
Adamek D, Dec M, Sobol G, Urbanowicz B, Jaworski M:
Giant cell ependymoma: a case report.
Clin Neurol Neurosurg
; 2008 Feb;110(2):176-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Histological, immunohistochemical and electron microscopic findings were consistent with high-
grade
ependymoma.
Especially striking was the presence of bizzare pleomorphic giant cells which predominated in the
tumor
tissue.
As a result the
diagnosis
of GCE was established.
This
type
of
neoplasm
necessitates, at least in theory, differentiation with
anaplastic
oligodendroglioma
, clear cell ependymoma, pleomorphic xanthoastrocytoma, giant cell glioblastoma, and subependymal giant cell astrocytoma.
In spite of apparently "worrisome" histology GCE seems to be
a neoplasm
with a relatively good prognosis.
Genetic Alliance.
consumer health - Ependymoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18006220.001).
[ISSN]
0303-8467
[Journal-full-title]
Clinical neurology and neurosurgery
[ISO-abbreviation]
Clin Neurol Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
39.
Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez Y Baena R, Gaetani P, Pelicci G, Allavena P:
Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1.
Eur J Cancer
; 2010 Dec;46(18):3383-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Human gliomas represent an unmet clinical challenge as nearly two-thirds of them are highly
malignant
lesions with fast progression, resistance to treatment and poor prognosis.
While receptor expression was similarly detected in low or high
grade
tumours, the uppermost scores of CX3CL1 were found in grades
III
-IV tumours:
oligodendrogliomas
,
anaplastic
astrocytomas and glioblastomas.
The high expression of CXC3L1 in the most severe forms of gliomas suggests the involvement of this chemokine and its receptor in the
malignant
behaviour of these tumours.
[MeSH-major]
Brain Neoplasms / metabolism. Chemokine CX3CL1 / metabolism. Glioblastoma / metabolism.
Neoplasm
Proteins / metabolism. Neoplastic Stem Cells / metabolism. Receptors, Interleukin-8A / metabolism
[MeSH-minor]
Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis.
Tumor
Cells, Cultured
Genetic Alliance.
consumer health - Glioblastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Ltd. All rights reserved.
(PMID = 20728344.001).
[ISSN]
1879-0852
[Journal-full-title]
European journal of cancer (Oxford, England : 1990)
[ISO-abbreviation]
Eur. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Chemokine CX3CL1; 0 / Neoplasm Proteins; 0 / Receptors, Interleukin-8A
40.
Cetin N, Dienel G, Gokden M:
CD117 expression in glial tumors.
J Neurooncol
; 2005 Nov;75(2):195-202
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The proportion of high
grade
tumors of all
tumor
types with detectable CD117 immunoreactivity was statistically significantly greater than low
grade
tumors, and glioblastoma and
anaplastic
oligodendroglioma
showed the highest staining
grade
.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Proto-Oncogene Proteins c-kit / metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1992 Nov 15;52(22):6139-43
[
1384954.001
]
[Cites]
Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):56-61
[
12610358.001
]
[Cites]
Expert Rev Anticancer Ther. 2003 Oct;3(5):595-614
[
14599084.001
]
[Cites]
J Neurosurg. 1987 Nov;67(5):697-705
[
3668638.001
]
[Cites]
J Pharmacokinet Biopharm. 1980 Jun;8(3):257-96
[
7420270.001
]
[Cites]
Clin Cancer Res. 2002 Oct;8(10):3034-8
[
12374669.001
]
[Cites]
Exp Neurol. 1996 Oct;141(2):214-24
[
8812155.001
]
[Cites]
Cancer Res. 2003 Aug 15;63(16):5114-7
[
12941842.001
]
[Cites]
Pathol Oncol Res. 2003;9(1):13-9
[
12704441.001
]
[Cites]
J Pediatr Hematol Oncol. 2003 Aug;25(8):644-8
[
12902920.001
]
[Cites]
J Neurosci Res. 1993 Dec 1;36(5):596-606
[
7511700.001
]
[Cites]
Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):51-5
[
12610357.001
]
[Cites]
J Neurosurg. 2002 Jul;97(1):177-83
[
12134909.001
]
[Cites]
Am J Clin Pathol. 2003 Mar;119(3):325-7
[
12645332.001
]
[Cites]
Brain Res Mol Brain Res. 1992 Sep;15(1-2):47-54
[
1331669.001
]
[Cites]
J Neurooncol. 1997 Dec;35(3):327-33
[
9440029.001
]
[Cites]
Am J Hematol. 2000 Nov;65(3):234-8
[
11074541.001
]
[Cites]
Blood. 1995 Oct 15;86(8):3132-8
[
7579408.001
]
[Cites]
Clin Cancer Res. 2004 Feb 15;10(4):1241-9
[
14977821.001
]
[Cites]
Leuk Res. 2004 May;28 Suppl 1:S11-20
[
15036937.001
]
[Cites]
Acta Neuropathol. 1995;89(2):158-65
[
7537428.001
]
[Cites]
Oncogene. 1998 Aug 13;17(6):795-800
[
9715282.001
]
[Cites]
Cancer Res. 1992 Jun 15;52(12):3498-502
[
1375870.001
]
[Cites]
EMBO J. 1987 Nov;6(11):3341-51
[
2448137.001
]
[Cites]
Microsc Res Tech. 1994 Apr 15;27(6):516-27
[
8012054.001
]
[Cites]
Nat Rev Drug Discov. 2002 Jul;1(7):493-502
[
12120256.001
]
[Cites]
Cancer Res. 2000 Sep 15;60(18):5143-50
[
11016641.001
]
[Cites]
Expert Rev Anticancer Ther. 2004 Feb;4(1):105-28
[
14748662.001
]
[Cites]
Am J Clin Pathol. 2003 Mar;119(3):339-45
[
12645334.001
]
[Cites]
Am J Surg Pathol. 2002 Apr;26(4):486-92
[
11914627.001
]
[Cites]
Cancer Metastasis Rev. 1999;18(3):387-400
[
10721492.001
]
[Cites]
Ann Hematol. 2001 May;80(5):302-7
[
11446735.001
]
[Cites]
J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92
[
12604685.001
]
[Cites]
J Neurosurg. 1994 Jun;80(6):1063-73
[
7514661.001
]
[Cites]
Neurosurgery. 1993 Jul;33(1):106-15
[
7689190.001
]
[Cites]
J Neurosci Res. 1997 Jan 1;47(1):1-15
[
8981233.001
]
[Cites]
Eur J Neurosci. 2002 Feb;15(3):575-82
[
11876786.001
]
[Cites]
Am J Clin Pathol. 2002 Feb;117(2):188-93
[
11865845.001
]
[Cites]
J Clin Invest. 2002 Aug;110(3):311-9
[
12163450.001
]
[Cites]
Biochem Biophys Res Commun. 1992 Jan 31;182(2):474-80
[
1370880.001
]
[Cites]
Am J Surg Pathol. 2003 Jul;27(7):1013-9
[
12826896.001
]
[Cites]
Am J Pathol. 1993 Jan;142(1):339-46
[
7678721.001
]
[Cites]
Oncology. 2003;65(3):187-97
[
14657591.001
]
[Cites]
Cancer Invest. 2004;22(1):106-16
[
15069768.001
]
[Cites]
Adv Exp Med Biol. 2003;532:141-51
[
12908555.001
]
[Cites]
Virchows Arch. 1994;424(2):135-41
[
7514077.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):870-2
[
11821475.001
]
[Cites]
Br J Haematol. 2002 Oct;119(1):106-8
[
12358909.001
]
[Cites]
Expert Rev Anticancer Ther. 2003 Oct;3(5):655-70
[
14599089.001
]
(PMID = 16132504.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / NS38230
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
41.
Chamberlain MC, Chowdhary SA, Glantz MJ:
Anaplastic astrocytomas: biology and treatment.
Expert Rev Neurother
; 2008 Apr;8(4):575-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
astrocytomas: biology and treatment.
Anaplastic
astrocytomas (AA),
WHO grade III
gliomas, comprise 10-15% of all glial neoplasms.
The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of
oligodendroglial
tumors, and
anaplastic oligodendrogliomas
in particular.
[MeSH-major]
Astrocytoma /
diagnosis
. Astrocytoma / therapy. Brain Neoplasms /
diagnosis
. Brain Neoplasms / therapy. Clinical Trials as Topic
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Clinical Trials
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18416660.001).
[ISSN]
1744-8360
[Journal-full-title]
Expert review of neurotherapeutics
[ISO-abbreviation]
Expert Rev Neurother
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
42.
Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T:
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
Cancer Sci
; 2009 Oct;100(10):1996-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We analyzed the genomic region spanning wild-
type
R132 of IDH1 by direct sequencing in 125 glial tumors.
In the present study, R172 mutation of the IDH2 gene was detected in one
anaplastic
astrocytoma.
IDH1 or IDH2 mutations were frequently in
oligodendrogliomas
(67%),
anaplastic
astrocytomas (62%),
anaplastic
oligoastrocytomas (75%),
anaplastic oligodendrogliomas
(50%), secondary glioblastomas (67%), gangliogliomas (38%), and
anaplastic
gangliogliomas (60%).
Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with
anaplastic
astrocytomas.
Our data suggest that IDH1 or IDH2 mutation plays a role in early
tumor
progression of several types of glioma and might arise from a common glial precursor.
[MeSH-major]
Biomarkers,
Tumor
/ genetics. Brain Neoplasms / genetics. Glioma / genetics. Isocitrate Dehydrogenase / genetics
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19765000.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
43.
El-Jawahri A, Patel D, Zhang M, Mladkova N, Chakravarti A:
Biomarkers of clinical responsiveness in brain tumor patients : progress and potential.
Mol Diagn Ther
; 2008;12(4):199-208
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biomarkers of clinical responsiveness in brain
tumor
patients : progress and potential.
Anaplastic
astrocytoma and glioblastoma multiforme represent
malignant
astrocytomas, which are the most common
type
of
malignant
gliomas.
Despite research efforts in cancer therapy, the prognosis of patients with
malignant
gliomas remains poor.
Research efforts in recent years have focused on investigating the cellular, molecular, and genetic pathways involved in the progression of
malignant
gliomas.
As a result, biomarkers have emerged as diagnostic, predictive, and prognostic tools that have the potential to transform the field of brain
tumor
diagnostics.
An increased understanding of the important molecular pathways that have been implicated in the progression of
malignant
gliomas has led to the identification of potential diagnostic, prognostic, and predictive biomarkers, some bearing clinical implications for targeted therapy.
Some of the most promising biomarkers to date include loss of chromosomes 1p/19q in
oligodendrogliomas
and expression of O-6-methylguanine-DNA methyltransferase (MGMT) or epidermal growth factor receptor (EGFR) status in glioblastomas.
Research into the clinical relevance and applicability of such biomarkers has the potential to revolutionize our approach to the
diagnosis
and treatment of patients with
malignant
gliomas.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms / chemistry. Glioma / chemistry
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Metastasis Rev. 2005 Jan;24(1):71-85
[
15785873.001
]
[Cites]
J Clin Oncol. 2004 May 15;22(10):1926-33
[
15143086.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
[Cites]
Curr Neurol Neurosci Rep. 2005 May;5(3):186-97
[
15865884.001
]
[Cites]
J Clin Oncol. 1998 Oct;16(10):3310-5
[
9779706.001
]
[Cites]
J Neurooncol. 2005 Apr;72(2):151-6
[
15925995.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3133-8
[
15284265.001
]
[Cites]
Clin Cancer Res. 2000 Oct;6(10 ):3937-43
[
11051241.001
]
[Cites]
Cancer Res. 1998 Mar 1;58(5):1068-73
[
9500473.001
]
[Cites]
Cancer Res. 1990 Dec 15;50(24):8017-22
[
2253244.001
]
[Cites]
J Neurooncol. 2007 May;83(1):91-3
[
17164975.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
[
11020580.001
]
[Cites]
J Clin Oncol. 2008 Jan 10;26(2):271-8
[
18182667.001
]
[Cites]
N Engl J Med. 2005 Nov 10;353(19):2012-24
[
16282176.001
]
[Cites]
N Engl J Med. 2000 Nov 9;343(19):1350-4
[
11070098.001
]
[Cites]
J Neurosci Res. 2000 Mar 15;59(6):722-30
[
10700009.001
]
[Cites]
J Clin Oncol. 2007 Oct 20;25(30):4722-9
[
17947719.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Mar 21;367(4):743-7
[
18191638.001
]
[Cites]
Neuro Oncol. 1999 Apr;1(2):124-37
[
11550308.001
]
[Cites]
Nat Genet. 2000 May;25(1):55-7
[
10802656.001
]
[Cites]
Brain Pathol. 1993 Jan;3(1):19-26
[
8269081.001
]
[Cites]
Genes Dev. 2001 Jun 1;15(11):1311-33
[
11390353.001
]
[Cites]
J Clin Oncol. 2004 Jan 1;22(1):133-42
[
14638850.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4
[
8864278.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104
[
11706939.001
]
[Cites]
Cancer Res. 2003 Oct 15;63(20):6613-25
[
14583454.001
]
[Cites]
Cancer Res. 2004 Oct 1;64(19):6892-9
[
15466178.001
]
[Cites]
Nat Rev Cancer. 2002 Aug;2(8):616-26
[
12154354.001
]
[Cites]
Anticancer Res. 2008 Jan-Feb;28(1A):15-9
[
18383819.001
]
[Cites]
Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104
[
16831080.001
]
[Cites]
Cancer Res. 2000 Dec 1;60(23):6617-22
[
11118044.001
]
[Cites]
Oncogene. 2003 Jul 31;22(31):4918-23
[
12894235.001
]
[Cites]
Cancer Res. 2003 Jun 1;63(11):2742-6
[
12782577.001
]
[Cites]
Dis Markers. 2004;20(2):35-43
[
15322312.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
[
9422557.001
]
[Cites]
Annu Rev Pathol. 2006;1:97-117
[
18039109.001
]
[Cites]
J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15
[
18091559.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
Cancer Res. 2000 Dec 15;60(24):6868-74
[
11156382.001
]
[Cites]
Cancer. 2006 May 15;106(10 ):2218-23
[
16568472.001
]
[Cites]
Nat Rev Cancer. 2004 Apr;4(4):296-307
[
15057289.001
]
[Cites]
Clin Cancer Res. 2002 May;8(5):1100-6
[
12006525.001
]
[Cites]
Ann Neurol. 2006 Dec;60(6):740-3
[
17192931.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1992;420(4):321-5
[
1314448.001
]
[Cites]
Lancet. 2002 Mar 23;359(9311):1011-8
[
11937180.001
]
[Cites]
Oncogene. 2003 Apr 17;22(15):2361-73
[
12700671.001
]
[Cites]
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
[
17317837.001
]
[Cites]
Cancer. 2007 Jul 1;110(1):13-24
[
17520692.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Nat Rev Neurosci. 2004 Oct;5(10):782-92
[
15378038.001
]
[Cites]
Brain. 2007 Dec;130(Pt 12):3336-41
[
17998256.001
]
[Cites]
Cancer Cell. 2002 Mar;1(2):125-8
[
12086870.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6
[
2236070.001
]
[Cites]
Cancer Res. 1999 Sep 1;59(17):4228-32
[
10485462.001
]
[Cites]
Neuro Oncol. 1999 Jan;1(1):44-51
[
11550301.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10 ):997-1003
[
15758010.001
]
[Cites]
Nat Rev Genet. 2001 Feb;2(2):120-9
[
11253051.001
]
[Cites]
Cancer. 1997 Aug 15;80(4):776-87
[
9264362.001
]
[Cites]
Cancer Res. 2001 Sep 15;61(18):6885-91
[
11559565.001
]
[Cites]
Cancer Res. 1999 Feb 15;59(4):793-7
[
10029064.001
]
[Cites]
J Natl Cancer Inst. 2005 Jun 15;97(12 ):880-7
[
15956649.001
]
[Cites]
J Neurooncol. 2003 Feb;61(3):267-73
[
12675321.001
]
[Cites]
Brain Pathol. 2004 Oct;14(4):399-405
[
15605987.001
]
(PMID = 18652516.001).
[ISSN]
1177-1062
[Journal-full-title]
Molecular diagnosis & therapy
[ISO-abbreviation]
Mol Diagn Ther
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01CA108633
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
New Zealand
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
71
44.
Mittelbronn M, Wolff M, Bültmann E, Nägele T, Capper D, Beck R, Meyermann R, Beschorner R:
Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy.
Hum Pathol
; 2005 Jul;36(7):854-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disseminating
anaplastic
brainstem
oligodendroglioma
associated with allelic loss in the
tumor
suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy.
Magnetic resonance imaging showed brainstem enlargement leading to the
diagnosis
of an inflammatory process.
In addition, the clinical picture, a monocytic cerebrospinal fluid pleocytosis with elevated protein and lactate and serum IgM antibodies to Mycoplasma pneumoniae favored this
diagnosis
.
Finally, a disseminating
anaplastic
oligodendroglioma
with allelic loss of the D19S246
tumor
suppressor candidate locus of chromosome 19 was diagnosed.
To our knowledge, this is the first case of a disseminating
anaplastic
brainstem
oligodendroglioma
associated with this specific allelic loss occurring in childhood.
[MeSH-major]
Brain Stem Neoplasms /
diagnosis
. Chromosomes, Human, Pair 19. Genes,
Tumor
Suppressor. Loss of Heterozygosity / genetics. Meningoencephalitis /
diagnosis
.
Oligodendroglioma
/
diagnosis
[MeSH-minor]
Brain Stem / pathology. Child.
Diagnosis
, Differential. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male
Genetic Alliance.
consumer health - Chromosome 9
.
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16084959.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Glucocorticoids
45.
Shibui S:
[Resent advances in chemotherapy for malignant brain tumors].
Gan To Kagaku Ryoho
; 2005 Apr;32(4):442-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Resent advances in chemotherapy for
malignant
brain tumors].
Most
malignant
brain tumors are resistant to the chemotherapeutic agents because of the existence of several mechanisms or substances such as the blood-brain barrier, genes and proteins.
Especially recent advances in the field of molecular biology have contributed to examination of the chemosensitivities of
tumor
cells.
Loss of chromosome 1 p and 19 q is considered to be closely related to chemosensitivity in
anaplastic oligodendrogliomas
.
This is one of the breakthroughs in the field of chemotherapy for
malignant
brain tumors.
Multi-institutional randomized controlled study by JCOG Brain
Tumor
Study Group is the first trial for the treatment of
malignant
astrocytomas under well-established quality control and quality assurance systems.
It can be a model of clinical trials for
malignant
brain tumors in Japan.
[MeSH-minor]
Antineoplastic Agents, Alkylating / therapeutic use. Clinical Trials, Phase II as Topic. Drug Resistance,
Neoplasm
. Humans. Nimustine / administration & dosage. Nitrosourea Compounds / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Procarbazine / administration & dosage. Quality Control. Randomized Controlled Trials as Topic
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15853207.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 0S726V972K / Nimustine; 35S93Y190K / Procarbazine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
[Number-of-references]
27
46.
Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, Kang JK, Kim MC, Hong YK:
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
J Korean Med Sci
; 2006 Aug;21(4):739-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Temozolomide chemotherapy in patients with recurrent
malignant
gliomas.
Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against
malignant
brain tumors, however, its activity has not been reported in an Asian population.
This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive
malignant
gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000.
Sixteen patients had glioblastoma multiforme (GBM), six with
anaplastic
astrocytoma, and three with
anaplastic
oligodendroglioma
.
Temozolomide demonstrated moderate activity in recurrent and progressive
malignant
gliomas without serious toxicity.
[MeSH-minor]
Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Brain / drug effects. Brain / pathology. Combined Modality Therapy. Drug Administration Schedule. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / chemically induced.
Neoplasm
Recurrence, Local. Survival Analysis. Treatment Outcome. Vomiting / chemically induced
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Neurosci. 2001 Jul;8(4):325-7
[
11437571.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):1036-8
[
15758016.001
]
[Cites]
J Clin Oncol. 2002 Mar 1;20(5):1375-82
[
11870182.001
]
[Cites]
J Clin Oncol. 2002 Mar 1;20(5):1383-8
[
11870183.001
]
[Cites]
Lancet Oncol. 2001 Sep;2(9):552-60
[
11905710.001
]
[Cites]
Cancer Treat Rev. 2002 Apr;28(2):115-20
[
12297119.001
]
[Cites]
Cancer. 1981 Jan 1;47(1):207-14
[
7459811.001
]
[Cites]
Cancer. 1985 Sep 1;56(5):1106-11
[
2990664.001
]
[Cites]
Cancer Res. 1987 Nov 15;47(22):5846-52
[
3664486.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2762-71
[
10561351.001
]
[Cites]
Br J Cancer. 2000 Sep;83(5):588-93
[
10944597.001
]
[Cites]
Ann Oncol. 2001 Feb;12(2):255-7
[
11300334.001
]
[Cites]
Ann Oncol. 2001 Feb;12(2):259-66
[
11300335.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Eur J Cancer. 1993;29A(7):940-2
[
8499146.001
]
[Cites]
J Clin Epidemiol. 1997 Apr;50(4):441-50
[
9179103.001
]
[Cites]
J Neurooncol. 1997 Sep;34(3):263-78
[
9258818.001
]
[Cites]
Cancer Chemother Pharmacol. 1997;40(6):484-8
[
9332462.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Br J Cancer. 2002 Feb 12;86(4):501-5
[
11870527.001
]
(PMID = 16891823.001).
[ISSN]
1011-8934
[Journal-full-title]
Journal of Korean medical science
[ISO-abbreviation]
J. Korean Med. Sci.
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
[Other-IDs]
NLM/ PMC2729901
47.
Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP:
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas.
Oncogene
; 2008 Mar 27;27(14):2097-108
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Astrocytic,
oligodendroglial
and mixed gliomas are the commonest gliomas in adults.
Co-deletions of total 1p and 19q are found in the majority of
oligodendrogliomas
and considered as a diagnostic marker and a prognostic indicator.
Total 1p deletions were rare (2%), however partial deletions involving 1p36 were frequently identified in
anaplastic
astrocytomas (22%) and glioblastomas (34%).
Our results indicate that 1p deletions are common
anaplastic
astrocytomas and glioblastomas but are distinct from the 1p abnormalities in
oligodendrogliomas
.
Genetics Home Reference.
consumer health - chromosome 1
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83
[
10560660.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
[
8790415.001
]
[Cites]
Cancer Res. 2000 Jan 15;60(2):417-24
[
10667596.001
]
[Cites]
Hum Mol Genet. 2000 May 22;9(9):1433-42
[
10814707.001
]
[Cites]
J Neurosurg. 2000 Jun;92(6):983-90
[
10839259.001
]
[Cites]
J Neuropathol Exp Neurol. 2000 Jun;59(6):544-58
[
10850867.001
]
[Cites]
J Clin Oncol. 2001 Jan 15;19(2):509-18
[
11208845.001
]
[Cites]
Am J Pathol. 2001 Apr;158(4):1253-62
[
11290543.001
]
[Cites]
Cell Growth Differ. 2001 Apr;12(4):201-10
[
11331249.001
]
[Cites]
Int J Oncol. 2001 Sep;19(3):609-12
[
11494043.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71
[
11556543.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):196-201
[
11801559.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8
[
11939587.001
]
[Cites]
Am J Pathol. 2002 Jul;161(1):313-9
[
12107116.001
]
[Cites]
Cancer Genet Cytogenet. 2002 Jun;135(2):147-59
[
12127399.001
]
[Cites]
Acta Neuropathol. 2002 Oct;104(4):357-62
[
12200621.001
]
[Cites]
Nat Med. 1997 Jun;3(6):682-5
[
9176498.001
]
[Cites]
Genes Chromosomes Cancer. 1998 May;22(1):9-15
[
9591629.001
]
[Cites]
Oncogene. 1999 Jul 15;18(28):4144-52
[
10435596.001
]
[Cites]
J Neurooncol. 2004 Nov;70(2):137-60
[
15674475.001
]
[Cites]
Clin Cancer Res. 2005 Feb 1;11(3):1119-28
[
15709179.001
]
[Cites]
Annu Rev Immunol. 2005;23:23-68
[
15771565.001
]
[Cites]
Cancer Res. 2005 Apr 1;65(7):2653-61
[
15805262.001
]
[Cites]
Adv Cancer Res. 2005;94:29-86
[
16095999.001
]
[Cites]
Ann Neurol. 2005 Sep;58(3):483-7
[
16130103.001
]
[Cites]
J Mol Med (Berl). 2005 Nov;83(11):917-26
[
16133418.001
]
[Cites]
Oncogene. 2006 Feb 23;25(8):1261-71
[
16205629.001
]
[Cites]
Nature. 2006 May 18;441(7091):315-21
[
16710414.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54
[
16957578.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94
[
17021403.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
Cell. 2007 Feb 9;128(3):459-75
[
17289567.001
]
[Cites]
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51
[
17549014.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Oct;35(2):170-5
[
12203781.001
]
[Cites]
J Urol. 2003 Mar;169(3):1138-42
[
12576869.001
]
[Cites]
J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26
[
12578221.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Apr;36(4):361-74
[
12619160.001
]
[Cites]
Cancer. 2003 May 1;97(9):2254-61
[
12712480.001
]
[Cites]
Brain Pathol. 2003 Oct;13(4):507-18
[
14655756.001
]
[Cites]
Mod Pathol. 2004 Jun;17(6):617-22
[
15133472.001
]
[Cites]
Brain Pathol. 2004 Apr;14(2):121-30
[
15193024.001
]
[Cites]
Br J Cancer. 2004 Sep 13;91(6):1105-11
[
15475940.001
]
[Cites]
Cancer Res. 1988 Jan 15;48(2):405-11
[
3335011.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
(PMID = 17934521.001).
[ISSN]
1476-5594
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Grant]
United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2650419; NLM/ UKMS4022
48.
Noshita N, Mashiyama S, Fukawa O, Asano S, Watanabe M, Tominaga T:
Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report.
Neurol Med Chir (Tokyo)
; 2010;50(2):161-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extracranial metastasis of
anaplastic
oligodendroglioma
with 1p19q loss of heterozygosity--case report.
We report a rare case of
anaplastic
oligodendroglioma
with extracranial metastasis, showing 1p19q co-deletion in both the brain tissue and the metastatic site.
A 53-year-old man first presented with a left frontal
tumor
.
The
tumor
was subtotally removed and irradiation was performed for the residual
tumor
and
tumor
bed.
Histological examination revealed
anaplastic
oligodendroglioma
, proved to be the same as the previous brain
tumor
.
We confirmed 1p19q loss of heterozygosity in both lesions, suggesting that 1p19q co-deletion might important to extracranial metastasis of
oligodendroglioma
.
[MeSH-major]
Brain Neoplasms / genetics. Brain Neoplasms / pathology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / secondary.
Oligodendroglioma
/ genetics.
Oligodendroglioma
/ secondary
[MeSH-minor]
Cervical Vertebrae / pathology. Chromosomes, Human, Pair 1 / genetics. DNA Mutational Analysis. Fatal Outcome. Frontal Lobe / pathology. Genetic Predisposition to Disease / genetics. Genotype. Humans. Loss of Heterozygosity / genetics. Lymph Nodes / pathology. Male. Middle Aged. Neck / pathology.
Neoplasm
Metastasis / genetics.
Neoplasm
Metastasis / pathology. Spinal Canal / pathology. Thoracic Wall / pathology. Thymus Gland / pathology
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20185886.001).
[ISSN]
1349-8029
[Journal-full-title]
Neurologia medico-chirurgica
[ISO-abbreviation]
Neurol. Med. Chir. (Tokyo)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
49.
Ty AU, See SJ, Rao JP, Khoo JB, Wong MC:
Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
Neurology
; 2006 Jan 24;66(2):247-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Oligodendroglial tumor
chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with
oligodendroglial
tumors.
In this study, all seven patients with
oligodendroglioma
(OD) and eight with
anaplastic
oligodendroglioma
(AO) had objective responses or stable disease.
Twenty-four Common Toxicity Criteria
Grade
3/4 adverse events were noted.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Asian Continental Ancestry Group. Brain Neoplasms / drug therapy. Brain Neoplasms / ethnology.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ ethnology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16434664.001).
[ISSN]
1526-632X
[Journal-full-title]
Neurology
[ISO-abbreviation]
Neurology
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
50.
Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K:
Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
Clin Cancer Res
; 2007 Dec 15;13(24):7341-56
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene expression-based molecular diagnostic system for
malignant
gliomas is superior to histological
diagnosis
.
In this study, we focused on
anaplastic
oligodendroglioma
and glioblastoma, which typically follow distinct clinical courses.
EXPERIMENTAL DESIGN: The expression of 3,456 genes in 32 patients, 12 and 20 of whom had prognostically distinct
anaplastic
oligodendroglioma
and glioblastoma, respectively, was measured by PCR array.
Next to unsupervised methods, we did supervised analysis using a weighted voting algorithm to construct a diagnostic system discriminating
anaplastic
oligodendroglioma
from glioblastoma.
The clinical utility was tested on a microarray-based data set of 50
malignant
gliomas from a previous study.
RESULTS: Unsupervised analysis showed divergent global gene expression patterns between the two
tumor
classes.
Applied to a gene expression data set from a previous study, our model correlated better with outcome than histologic
diagnosis
, and also displayed 96.6% (28 of 29) consistency with the molecular classification scheme used for these histologically controversial gliomas in the original article.
Furthermore, we observed that histologically diagnosed glioblastoma samples that shared
anaplastic
oligodendroglioma
molecular characteristics tended to be associated with longer survival.
CONCLUSIONS: Our molecular diagnostic system showed reproducible clinical utility and prognostic ability superior to traditional histopathologic
diagnosis
for
malignant
glioma.
[MeSH-major]
Brain Neoplasms /
diagnosis
. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Glioblastoma /
diagnosis
. Glioblastoma / genetics.
Oligodendroglioma
/
diagnosis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18094416.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
51.
Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E:
Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
Minim Invasive Neurosurg
; 2007 Oct;50(5):273-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Twenty-seven patients (18 male, 9 female; mean age 42 years; range 11-77 years; 8 low-
grade
and 11 high-
grade
astrocytomas or mixed gliomas, 8
oligodendrogliomas
) underwent MET PET studies preoperatively.
RESULTS: MET PET
tumor
uptake was detected in 26 of 27 patients (96.3%).
The quantitative MET
tumor
standardized uptake value (SUV) ratio was significantly higher in
malignant
gliomas and
oligodendrogliomas
than in low-
grade
gliomas (2.76/2.62 vs. 1.67, p=0.03).
Focal uptake corresponded to
malignant
glioma histology in 66.7%, and uniform global uptake to
oligodendroglial
histology in 72.7%.
In
oligodendrogliomas
, global MET uptake constituted 81.5% (range 53.8-135%) of the MRI T(1)
tumor
volume on average and was limited to the MRI FLAIR
tumor
volume in 86% (7/8) of patients.
CONCLUSION: MET PET image fusion may facilitate the targeting of
anaplastic
foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify
oligodendroglial
histology preoperatively as well as characterize biologically active
tumor
volumes within MRI T(1)/FLAIR
tumor
areas of candidate patients for resection.
[MeSH-minor]
Adolescent. Adult. Aged. Carbon Radioisotopes. Child.
Diagnosis
, Differential. Female. Humans. Image Processing, Computer-Assisted / instrumentation. Image Processing, Computer-Assisted / methods. Male. Methionine / metabolism. Middle Aged.
Oligodendroglioma
/ pathology.
Oligodendroglioma
/ radionuclide imaging.
Oligodendroglioma
/ surgery. Predictive Value of Tests. Preoperative Care / instrumentation. Preoperative Care / methods. Sensitivity and Specificity
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
Hazardous Substances Data Bank.
(L)-Methionine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18058643.001).
[ISSN]
0946-7211
[Journal-full-title]
Minimally invasive neurosurgery : MIN
[ISO-abbreviation]
Minim Invasive Neurosurg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
52.
Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W, Radiation Therapy Oncology Group (RTOG), North Central Cancer Treatment Group (NCCTG), Southwest Oncology Group (SWOG), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Eastern Cooperative Oncology Group (ECOG):
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.
Int J Radiat Oncol Biol Phys
; 2010 Jul 1;77(3):662-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed
anaplastic oligodendrogliomas
: radiation therapy oncology group trial 9402.
PURPOSE: Radiation Therapy Oncology Group 9402 compared procarbazine, lomustine, and vincristine (PCV) chemotherapy plus radiation therapy (PCV + RT) vs. RT alone for
anaplastic
oligodendroglioma
.
For those
who
died, MMSE scores remained stable initially, whereas B-QOL slowly declined; both declined rapidly in the last year of life and similarly between arms.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2010 Elsevier Inc. All rights reserved.
[Cites]
J Clin Oncol. 2000 Feb;18(3):646-50
[
10653880.001
]
[Cites]
Arch Neurol. 1990 Jan;47(1):49-52
[
2294894.001
]
[Cites]
J Clin Oncol. 2002 Aug 15;20(16):3445-53
[
12177105.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2519-24
[
12829670.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2529-36
[
12829672.001
]
[Cites]
J Clin Oncol. 2004 Jan 1;22(1):157-65
[
14701778.001
]
[Cites]
J Psychiatr Res. 1975 Nov;12(3):189-98
[
1202204.001
]
[Cites]
Neurology. 1990 Aug;40(8):1225-30
[
2381530.001
]
[Cites]
Ann Neurol. 1990 Dec;28(6):818-22
[
2178330.001
]
[Cites]
Neurosurgery. 1992 Jul;31(1):78-82
[
1641113.001
]
[Cites]
J Am Geriatr Soc. 1992 Sep;40(9):922-35
[
1512391.001
]
[Cites]
J Neurooncol. 1992 Nov;14(3):243-53
[
1460487.001
]
[Cites]
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
[
8433390.001
]
[Cites]
J Clin Oncol. 1998 Jun;16(6):2195-201
[
9626221.001
]
[Cites]
Lifetime Data Anal. 2005 Jun;11(2):151-74
[
15940822.001
]
[Cites]
J Clin Epidemiol. 2005 Dec;58(12):1217-9
[
16291464.001
]
[Cites]
Stat Med. 2006 Jan 15;25(1):143-63
[
16025541.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Dec 1;24(34):5427-33
[
17135644.001
]
[Cites]
Neuro Oncol. 2007 Jan;9(1):53-62
[
17018697.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):71-8
[
18164829.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):64-70
[
18406884.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):59-64
[
10924972.001
]
(PMID = 19783377.001).
[ISSN]
1879-355X
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U10 CA037422-15; None / None / / U10 CA021661-30; United States / NCI NIH HHS / CA / U10 CA021661-31S1; United States / NCI NIH HHS / CA / U10 CA021661-27S2; None / None / / U10 CA021661-28S1; United States / NCI NIH HHS / CA / U10 CA021661-25; United States / NCI NIH HHS / CA / U10 CA037422-12; None / None / / U10 CA021661-27; United States / NCI NIH HHS / CA / U10 CA021661-28S1; United States / NCI NIH HHS / CA / U10 CA037422-19; None / None / / U10 CA021661-32S2; United States / NCI NIH HHS / CA / U10 CA021661-28; None / None / / U10 CA037422-19; None / None / / U10 CA037422-16; None / None / / U10 CA021661-25; United States / NCI NIH HHS / CA / U10 CA021661-32S4; United States / NCI NIH HHS / CA / U10 CA037422-20; United States / NCI NIH HHS / CA / U10 CA037422-22S1; United States / NCI NIH HHS / CA / U10 CA021661-32S1; None / None / / U10 CA037422-22; United States / NCI NIH HHS / CA / U10 CA021661-31; United States / NCI NIH HHS / CA / U10 CA021661-32; None / None / / U10 CA037422-15; None / None / / U10 CA021661-24; None / None / / U10 CA021661-27S1; United States / NCI NIH HHS / CA / U10 CA037422-18; None / None / / U10 CA021661-28; None / None / / U10 CA021661-32S3; None / None / / U10 CA021661-32S4; United States / NCI NIH HHS / CA / U10 CA021661-30; United States / NCI NIH HHS / CA / U10 CA037422-16; United States / NCI NIH HHS / CA / U10 CA037422-17; United States / NCI NIH HHS / CA / U10 CA021661-32S3; United States / NCI NIH HHS / CA / U10 CA021661-32S2; None / None / / U10 CA037422-21; United States / NCI NIH HHS / CA / U10 CA037422-21; None / None / / U10 CA021661-24S1; None / None / / U10 CA037422-17; None / None / / U10 CA021661-29; None / None / / U10 CA037422-12; None / None / / U10 CA021661-31S1; None / None / / U10 CA037422-14; None / None / / U10 CA021661-32; United States / NCI NIH HHS / CA / U10 CA037422-14; None / None / / U10 CA037422-22S1; United States / NCI NIH HHS / CA / U10 CA037422-21S1; None / None / / U10 CA037422-20; None / None / / U10 CA021661-31; None / None / / U10 CA021661-27S2; United States / NCI NIH HHS / CA / U10 CA021661-24; United States / NCI NIH HHS / CA / U10 CA021661-26; United States / NCI NIH HHS / CA / U10 CA021661-27S1; United States / NCI NIH HHS / CA / U10 CA021661-27; United States / NCI NIH HHS / CA / U10 CA021661-24S1; United States / NCI NIH HHS / CA / U10 CA037422-22; United States / NCI NIH HHS / CA / U10 CA037422-13; None / None / / U10 CA037422-13; None / None / / U10 CA037422-18; United States / NCI NIH HHS / CA / U10 CA021661-29; None / None / / U10 CA037422-21S1; None / None / / U10 CA021661-26; None / None / / U10 CA021661-32S1
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
[Other-IDs]
NLM/ NIHMS123692; NLM/ PMC2878934
53.
Gresner SM, Liberski PP:
[Significance and prospects of study on molecular alterations in oligodendrogliomas].
Neurol Neurochir Pol
; 2007 Jul-Aug;41(4):333-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Significance and prospects of study on molecular alterations in
oligodendrogliomas
].
Oligodendroglial
tumours represent
a type
of tumours in which molecular alterations may become a significant prognostic factor.
Oligodendrogliomas
show distinct genetic alterations, allowing us to distinguish them from other types of gliomas.
Conversely, allelic loss on chromosome 10q, observed in many
anaplastic oligodendrogliomas
, predicts rather poor outcome.
The present paper is a compilation of the newest information on the characteristics of the genetic alterations related to the clinical course of
oligodendrogliomas
, which seems to be important for the proper diagnostics and selection of the appropriate methods of treatment.
[MeSH-major]
Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Loss of Heterozygosity / genetics.
Oligodendroglioma
/ genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17874342.001).
[ISSN]
0028-3843
[Journal-full-title]
Neurologia i neurochirurgia polska
[ISO-abbreviation]
Neurol. Neurochir. Pol.
[Language]
pol
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Poland
[Number-of-references]
33
54.
Zada G, McNatt SA, Gonzalez-Gomez I, McComb JG:
Anaplastic intraventricular oligodendroglioma: case report and review of the literature.
Surg Neurol
; 2009 Jun;71(6):693-700
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
intraventricular
oligodendroglioma
: case report and review of the literature.
BACKGROUND: Intraventricular
oligodendroglioma
remains a rare
diagnosis
, with high-
grade
/
anaplastic
IVO being an even rarer subtype.
These lesions vary in regard to
tumor
grading and clinical presentation, as compared with their intraparenchymal counterparts.
A case report and review of the previous literature regarding IVO and
tumor
grading were conducted.
CASE DESCRIPTION: A case report of a patient with an
anaplastic
oligodendroglioma
confined entirely within the ventricular system is presented.
The literature regarding the clinical presentation, methodology of
diagnosis
, and treatment of IVO was reviewed.
Only 2 previous case reports of high-
grade
/
anaplastic
IVO were identified.
Accurate
diagnosis
of these lesions, including immunohistochemistry, electron microscopy, and molecular/chromosomal subtyping, is imperative.
Adjuvant therapies may differ significantly according to the
tumor grade
and molecular subtype.
CONCLUSIONS: Intraventricular
oligodendroglioma
remains an infrequently encountered lesion, yet is usually found to be low
grade
at the time of surgery.
Anaplastic
IVO is an exceedingly rare lesion, with only 3 case reports in the literature.
[MeSH-major]
Cerebral Ventricle Neoplasms /
diagnosis
. Cerebral Ventricle Neoplasms / surgery.
Oligodendroglioma
/
diagnosis
.
Oligodendroglioma
/ surgery
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18291495.001).
[ISSN]
0090-3019
[Journal-full-title]
Surgical neurology
[ISO-abbreviation]
Surg Neurol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
24
55.
Schiffer D, Manazza A, Tamagno I:
Nestin expression in neuroepithelial tumors.
Neurosci Lett
; 2006 May 29;400(1-2):80-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
As an early marker of differentiation, Nestin is almost not expressed in diffuse astrocytomas, variably expressed in
anaplastic
astrocytomas and strongly and irregularly expressed in glioblastomas.
Negative in
oligodendrogliomas
, it stains ependymomas and shows a gradient of expression in pilocytic astrocytomas.
In glioblastomas, Nestin distribution does not completely correspond to that of GFAP and Vimentin with which its expression varies in
tumor
cells in a complementary way, as confirmed by confocal microscopy.
Tumor
cells can thus either derive from or differentiate toward the neurocytogenetic stages.
Completely negative cells of invasive or recurrent glioblastomas may represent
malignant
selected clones after accumulation of mutations or early stem cells not expressing antigens.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16529857.001).
[ISSN]
0304-3940
[Journal-full-title]
Neuroscience letters
[ISO-abbreviation]
Neurosci. Lett.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Ki-67 Antigen; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin
56.
Xiang C, Sarid R, Cazacu S, Finniss S, Lee HK, Ziv-Av A, Mikkelsen T, Brodie C:
Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells.
Biochem Biophys Res Commun
; 2007 Oct 26;362(3):612-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In contrast, RTVP-1 and RTVP-1b showed similar patterns of expression in astrocytic tumors; highly expressed in glioblastomas as compared to normal brains, low-
grade
astrocytomas and
anaplastic oligodendrogliomas
.
[MeSH-major]
Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism.
Neoplasm
Proteins / biosynthesis.
Neoplasm
Proteins / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
[MeSH-minor]
Alternative Splicing. Amino Acid Sequence. Base Sequence. Cell Line,
Tumor
. Cell Movement. Cell Proliferation. Cloning, Molecular. Humans. Molecular Sequence Data. Protein Isoforms. Tissue Distribution
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17825796.001).
[ISSN]
0006-291X
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA-R21-96965; United States / NCI NIH HHS / CA / R24 CA095809
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
57.
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C:
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Clin Cancer Res
; 2009 Sep 15;15(18):5753-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
EGFRvIII deletion mutations in pediatric high-
grade
glioma and response to targeted therapy in pediatric glioma cell lines.
We have sought to clarify the role of EGFR in pediatric high-
grade
glioma (HGG).
No kinase or extracellular domain mutations were observed; however, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two
anaplastic oligodendrogliomas
and a gliosarcoma overexpressing EGFRvIII in the absence of gene amplification and coexpressing platelet-derived growth factor receptor alpha.
Pediatric glioblastoma cells transduced with wild-
type
or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-
type
PTEN.
[MeSH-minor]
Adolescent. Blotting, Western. Cell Proliferation / drug effects. Child. Erlotinib Hydrochloride. Humans. Prognosis. Quinazolines / pharmacology. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity.
Tumor
Cells, Cultured
Genetic Alliance.
consumer health - Glioma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Clin Cancer Res. 2009 Nov 15;15(22):7110
(PMID = 19737945.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United Kingdom / Cancer Research UK / / C1178/A10294; United Kingdom / Cancer Research UK / / C309/A2187; United Kingdom / Cancer Research UK / / C309/A8274
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Quinazolines; 0 / epidermal growth factor receptor VIII; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
58.
Higgins RJ, Dickinson PJ, LeCouteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN:
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.
J Neurooncol
; 2010 May;98(1):49-55
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (
WHO
2007) criteria for classification of human gliomas.
A total of 19 canine astrocytomas were classified as follows:
grade
IV (GBM) n = 7;
grade III
n = 5; and
grade
II, n = 7.
Thirty-eight
oligodendrogliomas
were classified as either
grade III
(
anaplastic
) n = 35 or low
grade
II n = 3.
Tissue microarray (TMA) immunohistochemistry was used to evaluate
tumor
expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas.
Findings were correlated with
tumor
classification and
grade
.
Increased EGFR expression was demonstrated in 57% of GBMs, 40% of
grade III
and 28% of
grade
II astrocytomas.
EGFR expression occurred in only 3% of
grade III
oligodendrogliomas
.
Increased expression of PDGFRalpha was demonstrated in 43% of GBMs, 20% of
grade III
, and 14% of
grade
II astrocytomas.
In the
oligodendroglioma
series, 94% of
grade III
tumors overexpressed PDGFRalpha.
IGFBP2 expression was detected in 71, 60 and 28% of GBMs,
grade III
and
grade
II astrocytomas respectively.
IGFBP2 expression occurred in 48% of
anaplastic
and in 33% of low
grade
oligodendrogliomas
.
Expression of EGFR, PDGFRalpha or IGFBP2 was not detected in normal canine
CNS
control TMA cores.
The incidence of overexpression of EGFR, PDGFRalpha and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar
type
and
grade
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Pathol. 1996 Jul;149(1):29-35
[
8686753.001
]
[Cites]
Endocrinology. 2001 Apr;142(4):1652-8
[
11250947.001
]
[Cites]
J Biol Chem. 2006 May 19;281(20):14085-91
[
16569642.001
]
[Cites]
Brain Pathol. 2002 Jan;12(1):95-107
[
11770905.001
]
[Cites]
Vet Pathol. 2004 Jan;41(1):10-9
[
14715963.001
]
[Cites]
J Neurooncol. 2008 May;88(1):11-7
[
18246408.001
]
[Cites]
Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4
[
8864278.001
]
[Cites]
Cancer Res. 1992 Aug 15;52(16):4550-3
[
1322795.001
]
[Cites]
J Neuropathol Exp Neurol. 2007 May;66(5):405-17
[
17483698.001
]
[Cites]
Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4
[
11322447.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Vet Pathol. 2003 Nov;40(6):659-69
[
14608019.001
]
[Cites]
J Histochem Cytochem. 2000 Aug;48(8):1103-10
[
10898803.001
]
[Cites]
J Natl Cancer Inst. 1971 Dec;47(6):1333-44
[
5120412.001
]
[Cites]
Vet Comp Oncol. 2006 Sep;4(3):132-40
[
19754810.001
]
[Cites]
Cancer Res. 2004 Jul 15;64(14):4783-9
[
15256447.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41
[
17606927.001
]
[Cites]
Cancer Res. 1999 Sep 1;59(17):4228-32
[
10485462.001
]
[Cites]
Brain Pathol. 2002 Jan;12(1):87-94
[
11770904.001
]
[Cites]
Neurosurgery. 1998 Feb;42(2):341-6
[
9482185.001
]
[Cites]
J Neurooncol. 2006 Jan;76(2):105-9
[
16205964.001
]
[Cites]
Cancer Res. 2003 Aug 1;63(15):4315-21
[
12907597.001
]
[Cites]
J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503
[
10850862.001
]
[Cites]
Neoplasia. 2005 Apr;7(4):397-406
[
15967117.001
]
(PMID = 19967449.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Insulin-Like Growth Factor Binding Protein 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
59.
Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L, Brandes AA:
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Br J Cancer
; 2007 Apr 10;96(7):1047-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gefitinib in patients with progressive high-
grade
gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
To investigate the role of gefitinib in patients with high-
grade
gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy.
Sixteen patients had glioblastoma, three patients had
anaplastic oligodendrogliomas
and nine patients had
anaplastic
astrocytoma.
No
grade
3-4 gefitinib-related toxicity was found.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy.
Neoplasm
Recurrence, Local / drug therapy. Quinazolines / therapeutic use
[MeSH-minor]
Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / secondary. Disease-Free Survival. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged.
Neoplasm
Staging.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ secondary. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2004 Jan 1;22(1):133-42
[
14638850.001
]
[Cites]
N Engl J Med. 2004 May 20;350(21):2129-39
[
15118073.001
]
[Cites]
Science. 2004 Jun 4;304(5676):1497-500
[
15118125.001
]
[Cites]
J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41
[
15292385.001
]
[Cites]
Science. 2004 Aug 20;305(5687):1163-7
[
15284455.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
[
15329413.001
]
[Cites]
Neurology. 2004 Sep 14;63(5):904-6
[
15365146.001
]
[Cites]
N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1
[
15376352.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
N Engl J Med. 2004 Dec 30;351(27):2883
[
15625347.001
]
[Cites]
Neurology. 2005 Apr 26;64(8):1444-5
[
15851741.001
]
[Cites]
J Natl Cancer Inst. 2005 May 4;97(9):643-55
[
15870435.001
]
[Cites]
J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
[
15956649.001
]
[Cites]
N Engl J Med. 2005 Nov 10;353(19):2012-24
[
16282176.001
]
[Cites]
Clin Cancer Res. 2002 Nov;8(11):3496-502
[
12429640.001
]
[Cites]
Ann Oncol. 2003 Jun;14(6):922-30
[
12796031.001
]
[Cites]
J Clin Oncol. 2003 Jun 15;21(12):2237-46
[
12748244.001
]
[Cites]
Lancet Neurol. 2003 Jul;2(7):404-9
[
12849118.001
]
[Cites]
J Clin Oncol. 2003 Jul 15;21(14):2787-99
[
12860957.001
]
[Cites]
J Clin Oncol. 2003 Oct 15;21(20):3798-807
[
12953099.001
]
[Cites]
JAMA. 2003 Oct 22;290(16):2149-58
[
14570950.001
]
(PMID = 17353924.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
[Other-IDs]
NLM/ PMC2360116
60.
Quon H, Abdulkarim B:
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
Cochrane Database Syst Rev
; 2008;(2):CD007104
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant treatment of
anaplastic oligodendrogliomas
and oligoastrocytomas.
Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to
grade
3.
Based on the differences in patient selection with respect to the definition of AO (2 versus 3 high risk
anaplastic
features) and sequence of treatment (RT and chemotherapy), the results from the two RCTs were not able to be considered for meta-analysis.
Tumors with 1p and 19q co-deletions are associated with better OS and may indicate a more chemo-responsive
tumor
.
[MeSH-major]
Astrocytoma / drug therapy. Brain Neoplasms / drug therapy.
Oligodendroglioma
/ drug therapy
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[UpdateIn]
Cochrane Database Syst Rev. 2014;5:CD007104
[
24833028.001
]
(PMID = 18425979.001).
[ISSN]
1469-493X
[Journal-full-title]
The Cochrane database of systematic reviews
[ISO-abbreviation]
Cochrane Database Syst Rev
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
11
61.
Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, Bernardeschi P:
A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia.
In Vivo
; 2006 Nov-Dec;20(6A):721-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase II clinical study on relapsed
malignant
gliomas treated with electro-hyperthermia.
The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed
malignant
glioma patients.
Twelve patients with histologically diagnosed
malignant
glioma entered the study.
Eight patients had glioblastoma multiforme, two had
anaplastic
astrocytoma
grade III
and two had
anaplastic
oligodendroglioma
.
ET appears to have some effectiveness in adults with relapsed
malignant
glioma.
[MeSH-major]
Brain Neoplasms / therapy. Electric Stimulation Therapy. Glioma / therapy. Hyperthermia, Induced.
Neoplasm
Recurrence, Local / therapy
Genetic Alliance.
consumer health - Malignant hyperthermia
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17203754.001).
[ISSN]
0258-851X
[Journal-full-title]
In vivo (Athens, Greece)
[ISO-abbreviation]
In Vivo
[Language]
eng
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
62.
Bruggers C, White K, Zhou H, Chen Z:
Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature.
J Pediatr Hematol Oncol
; 2007 May;29(5):319-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extracranial relapse of an
anaplastic
oligodendroglioma
in an adolescent: case report and review of the literature.
Oligodendroglioma
is an uncommon childhood
tumor
and is more chemosensitive than other
malignant
glial neoplasms.
Treatment involves gross total resection, and if
anaplastic
, radiation and chemotherapy.
We report a child with a low-
grade oligodendroglioma
that recurred as a high-
grade oligodendroglioma
and ultimately as extraneural systemic relapse.
This chemotherapy may be promising in treating
malignant oligodendroglioma
.
[MeSH-major]
Brain Neoplasms /
diagnosis
.
Neoplasm
Recurrence, Local /
diagnosis
.
Oligodendroglioma
/
diagnosis
. Pleural Neoplasms /
diagnosis
[MeSH-minor]
Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Pleural Effusion,
Malignant
/
diagnosis
. Pleural Effusion,
Malignant
/ therapy. Positron-Emission Tomography / methods. Recurrence
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17483710.001).
[ISSN]
1077-4114
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
63.
Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY:
EGFR tyrosine kinase domain mutations in human gliomas.
Neurology
; 2005 Apr 26;64(8):1444-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas,
anaplastic oligodendrogliomas
, and low-
grade
gliomas.
[MeSH-minor]
Astrocytoma / drug therapy. Astrocytoma / enzymology. Astrocytoma / genetics. Carcinoma / drug therapy. Carcinoma / enzymology. Carcinoma / genetics. DNA Mutational Analysis. Drug Resistance,
Neoplasm
/ genetics. Genetic Testing. Glioblastoma / drug therapy. Glioblastoma / enzymology. Glioblastoma / genetics. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / genetics.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ enzymology.
Oligodendroglioma
/ genetics. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Structure, Tertiary / genetics. Quinazolines / pharmacology. Quinazolines / therapeutic use
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15851741.001).
[ISSN]
1526-632X
[Journal-full-title]
Neurology
[ISO-abbreviation]
Neurology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
64.
Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY:
The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.
J Korean Neurosurg Soc
; 2008 Oct;44(4):222-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high
grade
gliomas : the preliminary results of single center prospective study.
OBJECTIVE:
Malignant
gliomas are the most common primary cerebral neoplasms in adults.
Despite multimodality treatments, the prognosis for patients with
malignant
glioma remains poor.
We report for the first time preliminary results of the treatment with CCRT of newly diagnosed
malignant
gliomas in Korean people.
METHODS: Thirty-two patients over the age of 17 years with newly diagnosed and histologically confirmed high-
grade
gliomas (HGG), from June 2004 to August 2007 were the subjects of this study.
Pathologically, glioblastoma,
anaplastic
astrocytoma,
anaplastic
oligodendroglioma
, and gliomatosis cerebri had been diagnosed in eighteen, eight, four, and two patients, respectively.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2008 May 1;26(13):2192-7
[
18445844.001
]
[Cites]
Br J Cancer. 2000 Apr;82(8):1371-80
[
10780513.001
]
[Cites]
Neurol Clin. 2007 Nov;25(4):1111-39, x
[
17964028.001
]
[Cites]
J Clin Oncol. 2007 Sep 10;25(26):4127-36
[
17827463.001
]
[Cites]
Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111
[
17027279.001
]
[Cites]
Tumori. 2006 Jul-Aug;92(4):299-305
[
17036520.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
Cancer Radiother. 2005 Sep;9(5):322-31
[
16095943.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Strahlenther Onkol. 2005 Mar;181(3):157-63
[
15756519.001
]
[Cites]
J Clin Oncol. 1998 Dec;16(12):3851-7
[
9850030.001
]
[Cites]
J Neurosurg. 1989 Dec;71(6):826-36
[
2585073.001
]
[Cites]
N Engl J Med. 1980 Dec 4;303(23):1323-9
[
7001230.001
]
[Cites]
J Neurosurg. 1978 Sep;49(3):333-43
[
355604.001
]
[Cites]
J Clin Oncol. 2002 Mar 1;20(5):1375-82
[
11870182.001
]
[Cites]
Ann Oncol. 2001 Feb;12(2):259-66
[
11300335.001
]
[Cites]
Br J Cancer. 2000 Sep;83(5):588-93
[
10944597.001
]
[Cites]
Can J Neurol Sci. 2007 Nov;34(4):402-10
[
18062446.001
]
(PMID = 19096681.001).
[ISSN]
2005-3711
[Journal-full-title]
Journal of Korean Neurosurgical Society
[ISO-abbreviation]
J Korean Neurosurg Soc
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Korea (South)
[Other-IDs]
NLM/ PMC2588321
[Keywords]
NOTNLM ; Concomitant chemoradiotherapy / Glioblastoma / High-grade glioma / Temozolomide
65.
Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT:
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
Neuro Oncol
; 2005 Jan;7(1):32-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-
grade
astrocytomas.
Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma
tumor
cell line in athymic mice.
In this phase 2 study, aprinocarsen was administered to patients with recurrent high-
grade
gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month).
Their median age was 46 years (range, 28-68 years), median Karnofsky performance status was 80 (range, 60-100), median
tumor
volume was 58 cm3 (range, 16-254 cm3), and histology included glioblastoma multiforme (n = 16),
anaplastic
oligodendroglioma
(n = 4), and
anaplastic
astrocytoma (n = 1).
No
tumor
responses were observed.
The observed toxicities were mild, reversible, and uncommon (
grade
3 thrombocytopenia [n = 3] and
grade
4 AST [n = 1]), and no coagulopathy or
CNS
bleeding resulted from this therapy.
This is the first study to use an antisense oligonucleotide or a specific PKC-alpha inhibitor in patients with high-
grade
gliomas.
The rapid deterioration seen in these patients could result from
tumor
growth or an effect of aprinocarsen on bloodbrain barrier integrity.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Pharmacol. 1996 Aug;50(2):236-42
[
8700129.001
]
[Cites]
Glia. 1999 Feb 1;25(3):240-6
[
9932870.001
]
[Cites]
J Biopharm Stat. 1997 Mar;7(1):171-8
[
9056596.001
]
[Cites]
J Clin Oncol. 1997 Sep;15(9):3121-8
[
9294475.001
]
[Cites]
J Biol Chem. 1998 Mar 13;273(11):6001-4
[
9497312.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3586-95
[
10550158.001
]
[Cites]
Clin Cancer Res. 1999 Nov;5(11):3357-63
[
10589745.001
]
[Cites]
Prog Neurobiol. 2001 Feb;63(3):321-36
[
11115728.001
]
[Cites]
Curr Oncol Rep. 2000 Sep;2(5):445-53
[
11122877.001
]
[Cites]
Neurosci Lett. 2001 Jan 19;297(3):163-6
[
11137753.001
]
[Cites]
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6
[
11687282.001
]
[Cites]
Curr Oncol Rep. 2002 Jan;4(1):37-46
[
11734112.001
]
[Cites]
Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40
[
11772309.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5
[
11796780.001
]
[Cites]
Clin Cancer Res. 2002 Apr;8(4):1042-8
[
11948111.001
]
[Cites]
Neurosci Lett. 2002 May 17;324(2):105-8
[
11988338.001
]
[Cites]
Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18
[
12110515.001
]
[Cites]
Clin Cancer Res. 2002 Jul;8(7):2188-92
[
12114419.001
]
[Cites]
J Anat. 2002 Jun;200(6):617-27
[
12162729.001
]
[Cites]
J Anat. 2002 Jun;200(6):639-46
[
12162731.001
]
[Cites]
Neuro Oncol. 2003 Apr;5(2):96-103
[
12672281.001
]
[Cites]
Lancet Neurol. 2003 Jul;2(7):404-9
[
12849118.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2940-9
[
12912940.001
]
[Cites]
J Pharm Sci. 1985 Feb;74(2):229-31
[
3989700.001
]
[Cites]
Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32
[
4042238.001
]
[Cites]
Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25
[
3689368.001
]
[Cites]
Nature. 1988 Aug 25;334(6184):661-5
[
3045562.001
]
[Cites]
Control Clin Trials. 1989 Mar;10(1):1-10
[
2702835.001
]
[Cites]
Cancer Res. 1989 Jun 15;49(12):3215-7
[
2720675.001
]
[Cites]
Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83
[
2783141.001
]
[Cites]
Cancer Res. 1990 Feb 1;50(3):677-85
[
2297708.001
]
[Cites]
Br J Cancer. 1992 Jul;66(1):10-9
[
1637658.001
]
[Cites]
Pharmacol Ther. 1993 Sep;59(3):257-80
[
8309991.001
]
[Cites]
J Biol Chem. 1994 Jun 10;269(23):16416-24
[
7911467.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6
[
7972137.001
]
[Cites]
Cancer Chemother Pharmacol. 1998;42(2):118-26
[
9654111.001
]
[Cites]
Anal Biochem. 1996 Mar 1;235(1):36-43
[
8850544.001
]
(PMID = 15701280.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
[Other-IDs]
NLM/ PMC1871621
66.
Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL:
Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
J Neurooncol
; 2007 May;83(1):1-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
mixed gliomas and
anaplastic
oligodendroglioma
in children: results from the CCG 945 experience.
PURPOSE: To review interpathologist
diagnosis
variability and survival of children treated for either
anaplastic
mixed glioma (AMG) or
anaplastic
oligodendroglioma
(AO) with surgery, irradiation and chemotherapy.
PATIENTS AND METHODS: Two hundred and fifty patients with an institutional
diagnosis
of
malignant
glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
Complete resection and cerebral
tumor
location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG.
However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or
anaplastic
mixed oligoastrocytoma (AOA) and only one had AO.
CONCLUSION:
Diagnosis
of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
[MeSH-major]
Central Nervous System Neoplasms /
diagnosis
. Central Nervous System Neoplasms / therapy. Glioma /
diagnosis
. Glioma / therapy.
Oligodendroglioma
/
diagnosis
.
Oligodendroglioma
/ therapy
[MeSH-minor]
Adolescent. Astrocytoma /
diagnosis
. Astrocytoma / therapy. Brain Neoplasms /
diagnosis
. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms /
diagnosis
. Spinal Cord Neoplasms / therapy. Survival Analysis
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosurg. 1998 Jul;89(1):52-9
[
9647172.001
]
[Cites]
Hepatology. 1991 Nov;14(5):751-5
[
1937381.001
]
[Cites]
Cancer. 2003 Sep 15;98(6):1243-52
[
12973849.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):636-45
[
10653879.001
]
[Cites]
J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104
[
9329453.001
]
[Cites]
Childs Nerv Syst. 1999 Nov;15(11-12):786-8
[
10603023.001
]
[Cites]
J Neurooncol. 1994;21(3):255-65
[
7699420.001
]
[Cites]
Surg Neurol. 2003 Nov;60(5):443-56
[
14572971.001
]
[Cites]
J Clin Oncol. 2003 Jan 15;21(2):251-5
[
12525516.001
]
[Cites]
J Neurosurg. 1995 Apr;82(4):536-47
[
7897512.001
]
[Cites]
J Neurooncol. 2003 May;63(1):49-54
[
12814254.001
]
[Cites]
J Chronic Dis. 1967 Aug;20(8):637-48
[
4860352.001
]
[Cites]
J Neurooncol. 1988;6(1):9-23
[
3294353.001
]
[Cites]
Neuro Oncol. 2003 Jul;5(3):197-207
[
12816726.001
]
[Cites]
Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5
[
12015841.001
]
[Cites]
Biometrics. 1977 Mar;33(1):159-74
[
843571.001
]
[Cites]
Pediatr Neurosurg. 2003 Sep;39(3):114-21
[
12876389.001
]
[Cites]
Curr Treat Options Oncol. 2000 Dec;1(5):459-68
[
12057153.001
]
[Cites]
J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71
[
7964897.001
]
[Cites]
N Engl J Med. 2002 Feb 7;346(6):420-7
[
11832530.001
]
[Cites]
J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3
[
2231292.001
]
[Cites]
J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5
[
7815084.001
]
[Cites]
J Neurosurg. 1998 Feb;88(2):215-20
[
9452226.001
]
(PMID = 17252186.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article; Randomized Controlled Trial
[Publication-country]
United States
67.
Preusser M, Haberler C, Hainfellner JA:
Malignant glioma: neuropathology and neurobiology.
Wien Med Wochenschr
; 2006 Jun;156(11-12):332-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant
glioma: neuropathology and neurobiology.
Malignant
gliomas may manifest at any age including congenital and childhood cases.
Malignant
gliomas comprise a spectrum of different
tumor
subtypes.
Within this spectrum, glioblastoma,
anaplastic
astrocytoma and
anaplastic
oligodendroglioma
share as basic features preferential location in cerebral hemispheres, diffuse infiltration of brain tissue, fast
tumor
growth with fatal outcome within months or years.
Vascular proliferates and tissue necrosis are characteristic features of
malignant
gliomas, in particular glioblastoma.
These features are most likely the consequence of rapidly increasing
tumor
mass that is inadequately oxygenized by the preexisting vasculature.
In
malignant
glioma, distinct molecular pathways including the p53 pathway, the RB pathway and the EGFR pathway show frequent alterations that seem to be pathogenetically relevant.
Methylguanine-methyltransferase (MGMT) promoter methylation status in glioblastoma and 1p19q deletion status in
anaplastic
oligodendroglioma
are associated with response to chemotherapy.
[MeSH-minor]
Adult. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Chromosome Aberrations. Female. Humans. Infant. Male.
Neoplasm
Invasiveness / pathology. Prognosis
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Cancer. 2000 Dec;36(18):2294-300
[
11094302.001
]
[Cites]
J Neurooncol. 2004 Nov;70(2):217-28
[
15674479.001
]
[Cites]
Int J Cancer. 2005 Jan 20;113(3):379-85
[
15455350.001
]
[Cites]
Neurosurgery. 2003 Jun;52(6):1425-34; discussion 1434-5
[
12762887.001
]
[Cites]
J Neurooncol. 2001 Feb;51(3):231-43
[
11407595.001
]
[Cites]
Neurology. 1996 Jan;46(1):203-7
[
8559376.001
]
[Cites]
Neurosurgery. 2004 Jun;54(6):1480-8; discussion 1488-9
[
15157306.001
]
[Cites]
J Neurooncol. 2004 Nov;70(2):229-43
[
15674480.001
]
[Cites]
Nat Rev Cancer. 2003 Jul;3(7):489-501
[
12835669.001
]
[Cites]
Am J Pathol. 1994 Nov;145(5):1175-90
[
7977648.001
]
[Cites]
Oncogene. 2004 Dec 16;23(58):9392-400
[
15558011.001
]
[Cites]
J Neurosurg. 1989 Apr;70(4):573-7
[
2926498.001
]
[Cites]
Nat Rev Genet. 2002 Jun;3(6):415-28
[
12042769.001
]
[Cites]
Int J Clin Pharmacol Ther. 2002 Aug;40(8):354-67
[
12467304.001
]
[Cites]
Exp Mol Med. 2004 Feb 29;36(1):1-12
[
15031665.001
]
[Cites]
Biotechniques. 2002 Sep;33(3):632, 634, 636-49
[
12238773.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
[
15977639.001
]
[Cites]
Nat Rev Cancer. 2004 Dec;4(12 ):988-93
[
15573120.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Ann Neurol. 1988 Apr;23(4):360-4
[
3382171.001
]
[Cites]
Mutat Res. 1985 Jan-Mar;145(1-2):1-16
[
3883145.001
]
[Cites]
Int J Cancer. 1994 Apr 15;57(2):172-5
[
8157354.001
]
[Cites]
N Engl J Med. 2005 Aug 25;353(8):811-22
[
16120861.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 Jan;64(1):10-4
[
15715080.001
]
[Cites]
Cancer Res. 2003 Sep 15;63(18):5821-8
[
14522905.001
]
[Cites]
Curr Opin Oncol. 2004 Nov;16(6):607-13
[
15627025.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):396-401
[
15549107.001
]
[Cites]
Ann Neurol. 1990 May;27(5):573-4
[
2360797.001
]
[Cites]
Semin Oncol. 2004 Oct;31(5):645-52
[
15497117.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10 ):997-1003
[
15758010.001
]
[Cites]
Acta Neuropathol. 2005 Jan;109(1):93-108
[
15685439.001
]
[Cites]
Hum Mol Genet. 2001 Apr;10(7):699-703
[
11257102.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10 ):987-96
[
15758009.001
]
(PMID = 16944363.001).
[ISSN]
0043-5341
[Journal-full-title]
Wiener medizinische Wochenschrift (1946)
[ISO-abbreviation]
Wien Med Wochenschr
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Austria
[Number-of-references]
34
68.
Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE:
Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
Tumori
; 2009 May-Jun;95(3):317-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term outcome of postoperative irradiation in patients with newly diagnosed
WHO grade III
anaplastic
gliomas.
PURPOSE: Patients with
anaplastic
gliomas have a more favorable overall survival than patients with glioblastomas.
In most analyses,
WHO grade III
and 1V tumors are not analyzed separately.
The present analysis reports outcome after postoperative radiotherapy in patients with
WHO grade III
gliomas.
PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with
WHO grade III
tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure
oligodendroglioma
in 11 patients.
After the primary
diagnosis
, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively.
Median overall survival was 7 months for patients with
anaplastic
astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure
oligodendrogliomas
.
CONCLUSION: Patients with
WHO grade III
anaplastic
astrocytomas,
oligodendrogliomas
and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
[MeSH-minor]
Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged.
Oligodendroglioma
/ pathology.
Oligodendroglioma
/ radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19688970.001).
[ISSN]
0300-8916
[Journal-full-title]
Tumori
[ISO-abbreviation]
Tumori
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
69.
Owen CM, Linskey ME:
Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle.
J Neurooncol
; 2009 May;93(1):139-49
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Diagnostic accuracy was calculated comparing biopsy
diagnosis
with final pathology in 11 patients
who
underwent subsequent surgical resection.
Of 18 lesions involving the corpus callosum, 13 (72.2%) were GBM 2 were
anaplastic
astrocytoma, and 1 each were found to be
anaplastic
oligodendroglioma
, primary central nervous system lymphoma (PCNSL) and tumescent MS.
Of 25 multifocal lesions,
malignant
primary brain
tumor
was diagnosed in 17 (68%) (11 GBM, 3 PCNSL, 2
anaplastic
ologodendroglioma, and 1
anaplastic
astrocytoma).
CONCLUSIONS: Stereotactic biopsy is an effective, safe and important technique for histologic
diagnosis
of brain lesions, particularly for multifocal and corpus callosum lesions.
Post-biopsy CT can be safely reserved for patients
who
demonstrate persistent bleeding through the biopsy needle.
[MeSH-major]
Biopsy, Needle / methods. Brain Diseases /
diagnosis
. Brain Diseases / surgery. Neuronavigation
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool.
Diagnosis
, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Young Adult
MedlinePlus Health Information.
consumer health - Brain Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Comput Aided Surg. 1998;3(2):51-6
[
9784952.001
]
[Cites]
Minim Invasive Neurosurg. 2002 Mar;45(1):11-5
[
11932818.001
]
[Cites]
Neurosurgery. 2001 Oct;49(4):830-5; discussion 835-7
[
11564243.001
]
[Cites]
Br J Neurosurg. 2006 Aug;20(4):222-6
[
16954072.001
]
[Cites]
Neurosurgery. 1996 Jan;38(1):170-6; discussion 176-8
[
8747966.001
]
[Cites]
Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS146-56; discussion ONS146-56
[
16888546.001
]
[Cites]
Acta Neurochir Suppl (Wien). 1985;35:70-4
[
3911747.001
]
[Cites]
Ann Surg Oncol. 1994 Sep;1(5):368-72
[
7850537.001
]
[Cites]
AJNR Am J Neuroradiol. 1991 Nov-Dec;12 (6):1165-75
[
1763744.001
]
[Cites]
J Neurosurg. 2006 Feb;104(2):233-7
[
16509497.001
]
[Cites]
J Neurosurg. 1998 Jul;89(1):31-5
[
9647169.001
]
[Cites]
J Neurooncol. 2005 Jun;73(2):173-9
[
15981109.001
]
[Cites]
Appl Neurophysiol. 1982;45(4-5):426-30
[
7036878.001
]
[Cites]
Surg Neurol. 1984 Sep;22(3):222-30
[
6379944.001
]
[Cites]
Surg Neurol. 1980 Oct;14(4):275-83
[
7001660.001
]
[Cites]
J Neurosurg. 2005 May;102(5):897-901
[
15926716.001
]
[Cites]
Neurosurg Rev. 1994;17 (1):59-66
[
8078610.001
]
[Cites]
J Neurooncol. 2006 Jan;76(1):65-70
[
16132501.001
]
[Cites]
J Clin Neurosci. 2004 Apr;11(3):263-7
[
14975414.001
]
[Cites]
Neurosurgery. 1987 Jun;20(6):930-7
[
3302751.001
]
[Cites]
Neurosurgery. 1996 Nov;39(5):907-12; discussion 912-4
[
8905744.001
]
[Cites]
Neuro Oncol. 2001 Jul;3(3):193-200
[
11465400.001
]
[Cites]
Br J Neurosurg. 2002 Apr;16(2):110-8
[
12046728.001
]
[Cites]
J Neurosurg. 1994 Aug;81(2):165-8
[
8027795.001
]
[Cites]
Neurol Res. 2005 Jun;27(4):358-62
[
15949232.001
]
[Cites]
J Neurosurg. 2002 Aug;97(2):370-87
[
12186466.001
]
[Cites]
Neurosurgery. 1994 Oct;35(4):682-94; discussion 694-5
[
7808612.001
]
[Cites]
J Neurosurg. 2001 Apr;94(4):545-51
[
11302651.001
]
[Cites]
J Neurosurg. 1999 Jan;90(1):160-8
[
10413173.001
]
[Cites]
Neurosurgery. 1983 Mar;12 (3):277-85
[
6341870.001
]
[Cites]
Surg Neurol. 2001 Dec;56(6):366-71; discussion 371-2
[
11755966.001
]
[Cites]
Acta Neurochir (Wien). 1981;57(3-4):213-34
[
6269368.001
]
(PMID = 19430891.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
33
70.
Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Ishii S, Takahashi JA, Kato K:
Using gene expression profiling to identify a prognostic molecular spectrum in gliomas.
Cancer Sci
; 2009 Jan;100(1):165-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The expression levels of these genes in 152 gliomas (100 glioblastomas, 21
anaplastic
astrocytomas, 19 diffuse astrocytomas, and 12
anaplastic oligodendrogliomas
) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique.
The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and
oligodendroglial
tumors that were more reliable than the traditional histological classification scheme.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19038000.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
71.
Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E:
Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
Zentralbl Neurochir
; 2006 Nov;67(4):204-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic and survival-related factors in patients with well-differentiated
oligodendrogliomas
.
Oligodendrogliomas
are brain tumors with unpredictable biological and clinical behavior.
The present study reviews 50 patients with well-differentiated (
WHO grade
II)
oligodendrogliomas
, located in the cerebral hemispheres and operated upon between 1980 and 1998.
Prognostic factors studied include patient's age and sex,
tumor
location and extent, preoperative KPS, and extent of the surgical resection.
The long-term outcome and survival are not significantly correlated with the patient's age and sex,
tumor
location and extent, preoperative KPS and procedure for resection.
Interestingly, cases with late recurrences (more than 4 years after surgery) and longer survival are significantly associated to negative GF expression or slight positivity, as compared with the variable and more often moderate immunoreactivity of cases with early
anaplastic
recurrences and shorter survival time.
The presented data suggest that low proliferation indices and negative GF expression are associated with longer survival in well-differentiated
oligodendrogliomas
.
[MeSH-major]
Brain Neoplasms / mortality.
Oligodendroglioma
/ mortality
[MeSH-minor]
Adolescent. Adult. Aged. Aging. Antineoplastic Agents / therapeutic use. Biomarkers,
Tumor
. Cell Proliferation. Child. Combined Modality Therapy. Female. Humans. Intercellular Signaling Peptides and Proteins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17106834.001).
[ISSN]
0044-4251
[Journal-full-title]
Zentralblatt für Neurochirurgie
[ISO-abbreviation]
Zentralbl. Neurochir.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
72.
Scopece L, Franceschi E, Cavallo G, Paioli A, Paioli G, Conforti R, Palmerini E, Berzioli C, Spagnolli F, Esposti RD, Crinò L:
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.
J Neurooncol
; 2006 Sep;79(3):299-305
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive
oligodendroglial
tumors.
BACKGROUND:
Oligodendroglial
tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary.
METHODS: In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive
oligodendroglial
tumors.
Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had
oligodendroglioma
, 3 patients had oligoastrocytoma, 11 patients had
anaplastic
oligodendroglioma
, 9 patients had
anaplastic
oligoastrocytoma.
Toxicity was mainly hematological, with
grade
3-4 neutropenia in 5 (15.6%) patients.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Glioma / drug therapy.
Neoplasm
Recurrence, Local / drug therapy
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurooncol. 1996 Feb;27(2):149-55
[
8699237.001
]
[Cites]
J Neurooncol. 1990 Dec;9(3):249-54
[
2086739.001
]
[Cites]
J Surg Oncol. 1999 Jul;71(3):167-70
[
10404133.001
]
[Cites]
Med Pediatr Oncol. 1998 Jul;31(1):16-8
[
9607424.001
]
[Cites]
J Neurosurg. 1996 Oct;85(4):597-601
[
8814162.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
J Clin Oncol. 2001 May 1;19(9):2449-55
[
11331324.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Neurology. 1998 Oct;51(4):1140-5
[
9781544.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2525-8
[
12829671.001
]
[Cites]
Ann Oncol. 2003 Dec;14(12):1727-31
[
14630676.001
]
[Cites]
Cancer. 2004 Nov 1;101(9):2079-85
[
15372474.001
]
[Cites]
J Neurooncol. 1991 Oct;11(2):165-70
[
1744684.001
]
[Cites]
Ann Oncol. 2003 Apr;14 (4):599-602
[
12649108.001
]
[Cites]
Br J Cancer. 2004 Sep 13;91(6):1038-44
[
15305187.001
]
[Cites]
J Clin Oncol. 1984 Mar;2(3):215-20
[
6321690.001
]
[Cites]
Cancer Chemother Pharmacol. 1992;29(5):339-42
[
1312906.001
]
[Cites]
J Clin Oncol. 1992 Jul;10(7):1074-7
[
1318951.001
]
(PMID = 16645720.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
73.
Chinot O:
[New place of the chemotherapy in gliomas].
Bull Cancer
; 2005 Apr;92(4):343-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
During these last 25 years, despite numerous phases
III
studies, standard of treatment in glioblastoma multiforme (GBM) consisted of surgery and post-operative radiotherapy, while benefit of chemotherapy was a matter of debate.
A phase
III
study, conducted by EORTC and NCI Canada and involving 573 patients, concluded clearly to the benefit of adding temozolomide during and after radiotherapy as adjuvant treatment.
In the same time, for
anaplastic
oligodendroglioma
(AO) the phase
III
study conducted by Cairncross, that compared radiotherapy to a schedule that deliver a chemotherapy with PCV followed by radiotherapy, failed to determine a significant benefit on overall survival, despite the particular chemosensitivity of theses tumors.
We review here the new place of chemotherapy in the adjuvant treatment of GBM and
anaplastic
gliomas, as well as the impact of these pivotal studies on second lines therapies, and future clinical research.
[MeSH-minor]
Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Clinical Trials, Phase
III
as Topic. Disease Progression. Glioblastoma / drug therapy. Glioblastoma / mortality. Glioblastoma / radiotherapy. Humans. Prognosis. Survival Rate
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15888391.001).
[ISSN]
1769-6917
[Journal-full-title]
Bulletin du cancer
[ISO-abbreviation]
Bull Cancer
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
[Number-of-references]
72
74.
Ng WH, Lim TC, Tan KK:
Disseminated spread of recurrent oligodendroglioma (WHO grade II).
J Clin Neurosci
; 2006 Jun;13(5):602-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disseminated spread of recurrent
oligodendroglioma
(
WHO grade
II).
Oligodendroglioma
is a relatively uncommon primary brain tumour.
The occurrence of metastatic dissemination of
oligodendroglioma
is rare and usually occurs in patients with
anaplastic
oligodendroglioma
.
The dissemination of
WHO Grade
II
oligodendroglioma
can occur and we report a patient with an initial
diagnosis
of a left temporal
oligodendroglioma who
presented with disseminated disease in the left temporal lobe, sellar region, medulla oblongata, both frontal lobes and ventricles more than 8 years later.
Histology at dissemination showed
anaplastic
oligodendroglioma
.
Similar reports of metastatic dissemination of
oligodendrogliomas
reveal that the tumours may remain as
WHO Grade
II or may progress to
anaplastic
oligodendroglioma
at metastasis.
However, regardless of the histological
grade
at metastasis, the prognosis of metastatic
oligodendroglioma
is poor.
[MeSH-major]
Neoplasms, Second Primary / radiography.
Oligodendroglioma
/ radiography
Genetic Alliance.
consumer health - Oligodendroglioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16697645.001).
[ISSN]
0967-5868
[Journal-full-title]
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
[ISO-abbreviation]
J Clin Neurosci
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Scotland
[Number-of-references]
31
75.
Omuro AM:
Exploring multi-targeting strategies for the treatment of gliomas.
Curr Opin Investig Drugs
; 2008 Dec;9(12):1287-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Unfortunately, results of first generation targeted therapy trials for
malignant
gliomas (glioblastomas and
anaplastic
forms of astrocytomas,
oligodendrogliomas
and oligoastrocytomas) have been disappointing.
A new generation of trials is seeking to define whether inhibiting multiple targets simultaneously through utilization of less specific, multi-targeting drugs, or through combination of two or more single-targeted drugs, can overcome
tumor
resistance.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19037835.001).
[ISSN]
1472-4472
[Journal-full-title]
Current opinion in investigational drugs (London, England : 2000)
[ISO-abbreviation]
Curr Opin Investig Drugs
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Drugs, Investigational; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
[Number-of-references]
84
76.
Sugita Y, Nakamura Y, Yamamoto M, Ogasawara S, Ohshima K, Shigemori M:
Expression of KIAA 0864 protein in neuroepithelial tumors: an analysis based on the presence of monoclonal antibody HFB-16.
J Neurooncol
; 2008 Sep;89(2):151-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Among the 55 NETs, a moderate-to-intense KA protein immunoreactivity was observed in 8 of 8 medulloblastomas, 1 of 1 central nervous system supratentorial primitive neuroectodermal
tumor
(
CNS
supratentorial PNET), 4 of 4 retinoblastomas, 1 of 1 neuroblastoma, 8 of 8 central neurocytomas, 4 of 4
oligodendrogliomas
, 4 of 4 oligoastrocytomas, 1 of 1 extraventricular neurocytoma, and 1 of 1 gangliocytoma.
No or a weak KA protein immunoreactivity was observed in 11 of 11 glioblastomas (GBs), 4 of 4
anaplastic
astrocytomas, 4 of 4 astrocytomas, and 4 of 4 pilocytic astrocytomas.
In addition, it could be a useful tool for performing the differential
diagnosis
between GBs and
CNS
supratentorial PNET.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Cell Biol. 1997 Jun 30;137(7):1603-13
[
9199174.001
]
[Cites]
Acta Neuropathol. 2005 Aug;110(2):127-34
[
15983829.001
]
[Cites]
Lab Invest. 1992 Mar;66(3):303-13
[
1538585.001
]
[Cites]
DNA Res. 1998 Dec 31;5(6):355-64
[
10048485.001
]
[Cites]
J Histochem Cytochem. 2005 Apr;53(4):423-30
[
15805417.001
]
[Cites]
Neuron. 2007 Feb 15;53(4):503-17
[
17296553.001
]
[Cites]
Am J Surg Pathol. 1999 May;23 (5):502-10
[
10328080.001
]
[Cites]
J Neurooncol. 2007 Apr;82(2):199-205
[
17039400.001
]
[Cites]
Genes Dev. 2003 Feb 15;17(4):476-87
[
12600941.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6
[
10468613.001
]
[Cites]
J Biol Chem. 2003 Jul 18;278(29):27216-23
[
12732640.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55
[
12430711.001
]
[Cites]
Genes Dev. 2001 Aug 1;15(15):1913-25
[
11485986.001
]
[Cites]
Clin Exp Metastasis. 2002;19(1):9-15
[
11918088.001
]
[Cites]
Differentiation. 2001 Sep;68(2-3):141-52
[
11686236.001
]
[Cites]
Mod Pathol. 2006 Jul;19(7):974-85
[
16648867.001
]
(PMID = 18458818.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Guanine Nucleotide Exchange Factors; 0 / RASGRP3 protein, human
77.
Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ:
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
J Neuropathol Exp Neurol
; 2007 Jun;66(6):545-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Panel review of
anaplastic
oligodendroglioma
from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in
diagnosis
, influence of 1p/19q loss, and correlations with outcome.
The
diagnosis
of
anaplastic
oligodendroglioma
(AOD) or
anaplastic
oligoastrocytoma (AOA) is subject to interobserver variation.
The aim of this study was to estimate consensus in typing and grading of these tumors using
tumor
material collected in a large prospective randomized phase
III
study and to correlate the consensus
diagnosis
with the 1p/19q status of the tumors and the clinical outcome.
The panel reached consensus on the
diagnosis
of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local
diagnosis
of AOA was confirmed with consensus.
The concordance on the panel
diagnosis
of AOD was high (intraclass correlation = 86%).
[MeSH-major]
Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Deletion.
Oligodendroglioma
/ genetics.
Oligodendroglioma
/ pathology
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17549014.001).
[ISSN]
0022-3069
[Journal-full-title]
Journal of neuropathology and experimental neurology
[ISO-abbreviation]
J. Neuropathol. Exp. Neurol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
78.
Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, Blanc JL, Lapierre F, Rigoard P, Milin S, Duthe F, Bonneau D, Larsen CJ, Karayan-Tapon L:
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study.
Br J Cancer
; 2008 Jun 3;98(11):1830-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Univariate analysis was followed by multivariate analysis according to a Cox model. p14(ARF), p16(INK4A) and PTEN expressions, and 10p 10q23, 10q26 and 13q LOH for the entire cohort, hTERT expression for high-
grade
tumours, EGFR for glioblastomas, 10q26 LOH for
grade III
tumours and
anaplastic oligodendrogliomas
were found to be correlated with overall survival on univariate analysis and age and
grade
on multivariate analysis only.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Decision Making. Humans. Loss of Heterozygosity. Middle Aged. Multivariate Analysis. Prognosis. Promoter Regions, Genetic. Prospective Studies. Telomerase / genetics.
Tumor
Suppressor Proteins / genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Oncol. 2006 Jun;28(6):1555-60
[
16685456.001
]
[Cites]
Cancer Lett. 2006 Feb 8;232(2):139-47
[
16139423.001
]
[Cites]
J Clin Oncol. 2006 Sep 20;24(27):4412-7
[
16983109.001
]
[Cites]
Br J Cancer. 2006 Oct 23;95(8):1062-9
[
17047653.001
]
[Cites]
Cell Prolif. 2007 Feb;40(1):14-23
[
17227292.001
]
[Cites]
Brain Res. 2007 Feb 23;1134(1):45-52
[
17196947.001
]
[Cites]
J Clin Oncol. 2007 Apr 20;25(12):1470-5
[
17442989.001
]
[Cites]
Brain Pathol. 2007 Jan;17(1):5-10
[
17493032.001
]
[Cites]
Cancer. 2007 Jul 1;110(1):13-24
[
17520692.001
]
[Cites]
Nat Rev Cancer. 2007 Oct;7(10):733-6
[
17882276.001
]
[Cites]
Cancer Res. 2007 Oct 1;67(19):8980-4
[
17908997.001
]
[Cites]
J Surg Oncol. 2004 Apr 1;86(1):34-40
[
15048678.001
]
[Cites]
J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43
[
10850866.001
]
[Cites]
N Engl J Med. 2000 Nov 9;343(19):1350-4
[
11070098.001
]
[Cites]
Clin Cancer Res. 2001 Aug;7(8):2387-95
[
11489817.001
]
[Cites]
Neuro Oncol. 1999 Jul;1(3):169-76
[
11550311.001
]
[Cites]
Arch Pathol Lab Med. 2002 Jan;126(1):42-8
[
11800646.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):592-8
[
11849778.001
]
[Cites]
Cancer Res. 2002 Mar 15;62(6):1790-6
[
11912156.001
]
[Cites]
Lancet. 2002 Mar 23;359(9311):1011-8
[
11937180.001
]
[Cites]
Clin Neuropathol. 2002 Mar-Apr;21(2):52-65
[
12005253.001
]
[Cites]
Br J Cancer. 2003 Feb 24;88(4):516-20
[
12592364.001
]
[Cites]
Clin Cancer Res. 2003 Apr;9(4):1461-8
[
12684420.001
]
[Cites]
J Neurosurg. 2003 Sep;99(3):467-73
[
12959431.001
]
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4884-90
[
14581362.001
]
[Cites]
Cancer Res. 2003 Oct 15;63(20):6962-70
[
14583498.001
]
[Cites]
Int J Oncol. 2003 Dec;23(6):1529-35
[
14612923.001
]
[Cites]
Neuropathology. 2007 Feb;27(1):10-20
[
17319279.001
]
[Cites]
J Neurooncol. 2007 Apr;82(2):141-50
[
17115285.001
]
[Cites]
J Clin Oncol. 2007 Apr 20;25(12):1459-60
[
17442986.001
]
[Cites]
Clin Cancer Res. 2004 Aug 1;10(15):4933-8
[
15297393.001
]
[Cites]
Oncol Rep. 2004 Oct;12(4):789-95
[
15375501.001
]
[Cites]
Nature. 1992 Oct 29;359(6398):845-8
[
1279432.001
]
[Cites]
J Korean Med Sci. 1995 Dec;10(6):442-8
[
8924230.001
]
[Cites]
Nat Genet. 1997 Sep;17(1):32-9
[
9288095.001
]
[Cites]
Oncogene. 1998 Apr 30;16(17):2259-64
[
9619835.001
]
[Cites]
Int J Cancer. 1999 Apr 20;84(2):150-4
[
10096247.001
]
[Cites]
Am J Pathol. 1999 Aug;155(2):387-94
[
10433932.001
]
[Cites]
Int J Cancer. 2005 Feb 10;113(4):581-7
[
15455376.001
]
[Cites]
Surg Neurol. 2005 Feb;63(2):162-9; discussion 169
[
15680662.001
]
[Cites]
Clin Cancer Res. 2005 Feb 15;11(4):1462-6
[
15746047.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):997-1003
[
15758010.001
]
[Cites]
Neurosurgery. 2005 Apr;56(4):802-10
[
15792519.001
]
[Cites]
Arch Pathol Lab Med. 2005 May;129(5):624-31
[
15859633.001
]
[Cites]
Cancer Res. 2005 May 15;65(10):4051-8
[
15899794.001
]
[Cites]
Drug Resist Updat. 2005 Feb-Apr;8(1-2):75-83
[
15939344.001
]
[Cites]
J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
[
15956649.001
]
[Cites]
J Clin Oncol. 2005 Aug 10;23(23):5294-304
[
15998902.001
]
[Cites]
Clin Neuropathol. 2005 Sep-Oct;24(5):209-18
[
16167544.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703
[
15936158.001
]
[Cites]
Surg Neurol. 2005 Oct;64(4):286-94; discussion 294
[
16229087.001
]
[Cites]
N Engl J Med. 2005 Nov 10;353(19):2012-24
[
16282176.001
]
[Cites]
Neurosurg Focus. 2006;20(4):E23
[
16709029.001
]
(PMID = 18506188.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; EC 6.5.1.- / DNA Repair Enzymes
[Other-IDs]
NLM/ PMC2410116
79.
Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, Schultz L:
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
J Neurooncol
; 2009 Mar;92(1):57-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Temozolomide single-agent chemotherapy for newly diagnosed
anaplastic
oligodendroglioma
.
The treatment of patients with
anaplastic
oligodendroglioma
(AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q.
Patients with AO with 1p/19q LOH can be safely treated with single-agent TMZ and do not appear to experience earlier or more frequent
tumor
progression.
[MeSH-major]
Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives.
Oligodendroglioma
/ drug therapy
[MeSH-minor]
Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Prognosis. Promoter Regions, Genetic / genetics.
Tumor
Suppressor Proteins / genetics
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuro Oncol. 2007 Jul;9(3):314-8
[
17435180.001
]
[Cites]
N Engl J Med. 2000 Nov 9;343(19):1350-4
[
11070098.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Lab Invest. 2007 Apr;87(4):392-7
[
17260000.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
Biometrics. 1995 Dec;51(4):1372-83
[
8589229.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
Neurosurgery. 1992 Jul;31(1):78-82
[
1641113.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Cytometry. 2002 Jan 1;47(1):52-5
[
11774351.001
]
[Cites]
J Neurooncol. 2006 Sep;79(2):153-7
[
16855865.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2499-503
[
16914310.001
]
[Cites]
J Neurooncol. 2008 Sep;89(2):187-93
[
18458821.001
]
(PMID = 19011763.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
80.
Hartmann C, von Deimling A:
Molecular pathology of oligodendroglial tumors.
Recent Results Cancer Res
; 2009;171:25-49
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular pathology of
oligodendroglial
tumors.
The term
oligodendroglioma
was created by Bailey, Cushing, and Bucy based on the observation that these tumors share morphological similarities with oligodendrocytes (Bailey and Cushing 1926; Bailey and Bucy 1929).
However, a convincing link between oligodendrocytes and
oligodendrogliomas
still needs to be shown.
Oligoastrocytomas or mixed gliomas are histologically defined by the presence of
oligodendroglial
and astrocytic components.
According to the
WHO
classification of brain tumors,
oligodendroglial
tumors are separated into
oligodendrogliomas
WHO grade
II (OII),
anaplastic oligodendrogliomas
WHO grade III
(OIII), oligoastrocytomas
WHO grade
II (OAII),
anaplastic
oligoastrocytomas
WHO grade III
(OAIII), and glioblastomas with
oligodendroglioma
component
WHO grade
IV (GBMo) (Louis et al. 2007).The perception of
oligodendroglial
tumors has changed in recent years.
The
diagnosis
of
oligodendroglioma
or oligoastrocytomas is made much more frequently than 10 years ago.
Treatment modalities have been advanced and novel concepts regarding the origin of
oligodendroglial
tumors have been developed.
This review focuses on recent developments with impact on the
diagnosis
and understanding of molecular mechanisms in
oligodendroglial
tumors.
[MeSH-major]
Brain Neoplasms / genetics. Brain Neoplasms / pathology.
Oligodendroglioma
/ genetics.
Oligodendroglioma
/ pathology
[MeSH-minor]
Chromosome Aberrations. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Genotype. Humans. Immunohistochemistry. Mutation. Prognosis.
Tumor
Suppressor Proteins / genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19322536.001).
[ISSN]
0080-0015
[Journal-full-title]
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
[ISO-abbreviation]
Recent Results Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
[Number-of-references]
172
81.
van den Bent MJ:
Anaplastic oligodendroglioma and oligoastrocytoma.
Neurol Clin
; 2007 Nov;25(4):1089-109, ix-x
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
oligodendroglioma
and oligoastrocytoma.
Until approximately 15 years ago, the
diagnosis
of an
oligodendroglioma
(OD) was merely as a pathologic entity.
The only clinical relevant meaning of this histologic
diagnosis
was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar
grade
.
Observations have led to the current tendency to consider 1p/19q loss low-
grade
and
anaplastic
oligodendroglioma a
separate biologic entity, at least within clinical trials, since they have a much better outcome.
[MeSH-major]
Astrocytoma / pathology. Brain Neoplasms / pathology.
Oligodendroglioma
/ pathology
Genetic Alliance.
consumer health - Anaplastic Oligoastrocytoma
.
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligoastrocytoma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for oligoastrocytoma
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17964027.001).
[ISSN]
0733-8619
[Journal-full-title]
Neurologic clinics
[ISO-abbreviation]
Neurol Clin
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
[Number-of-references]
75
82.
Poulsen HS:
[Gliomas in adults: primary non-surgical treatment].
Ugeskr Laeger
; 2006 Nov 20;168(47):4082-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Radiation therapy has a definite place in the treatment of low-
grade
gliomas, but the timing is a matter of dispute.
Anaplastic
astrocytomas should be treated with postoperative radiation therapy with or without adjuvant chemotherapy.
Anaplastic
oligodendroglioma
should be treated with radiation therapy only.
[MeSH-minor]
Adult. Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Chemotherapy, Adjuvant. Ependymoma / drug therapy. Ependymoma / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans.
Oligodendroglioma
/ drug therapy.
Oligodendroglioma
/ radiotherapy. Radiotherapy Dosage. Radiotherapy, Adjuvant
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17134603.001).
[ISSN]
1603-6824
[Journal-full-title]
Ugeskrift for laeger
[ISO-abbreviation]
Ugeskr. Laeg.
[Language]
dan
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
10
83.
Bulnes S, Lafuente JV:
VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas.
J Mol Neurosci
; 2007;33(2):163-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
During
tumor
development, neoplastic cells switch to an angiogenic phenotype, playing a significant role in the expression of the vascular endothelial growth factor (VEGF).
Histopathology allows us to identify microtumors as classic
oligodendrogliomas
(CO; mean PI of 6.01 +/- 2.8%) and macrotumors as
anaplastic oligodendrogliomas
(AO; mean PI of 14.06 +/- 5%).
Classic
oligodendrogliomas
show scarce VEGF165 expression whereas
anaplastic
ones display VEGF165 protein level 100-fold increased respect to CO.
Astrocytes, neoplastic, and endothelial cells show differential immunostaining patterns from the border to the core of
neoplasm
.
Anaplastic
gliomas displaying VEGF-positive intratumor capillaries correspond to the highest PI values.
To identify the "angiogenic switch," we propose the glioma stage characterized by VEGF immunopositive neoplastic cells inside the
tumor
and positive endothelial cells surrounding it.
[MeSH-minor]
Animals. Female. Fetus / drug effects. Humans.
Neoplasm
Staging. Pregnancy. Rats. Rats, Sprague-Dawley
Hazardous Substances Data Bank.
N-NITROSO-N-ETHYLUREA
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17917075.001).
[ISSN]
0895-8696
[Journal-full-title]
Journal of molecular neuroscience : MN
[ISO-abbreviation]
J. Mol. Neurosci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Alkylating Agents; 0 / Vascular Endothelial Growth Factor A; P8M1T4190R / Ethylnitrosourea
84.
Gilbert MR, Loghin M:
The Treatment of Malignant Gliomas.
Curr Treat Options Neurol
; 2005 Jul;7(4):293-303
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The Treatment of
Malignant
Gliomas.
The optimal management of patients with
malignant
gliomas begins with the accurate determination of the pathologic
diagnosis
based on adequate sampling of the
tumor
.
Clear differences in prognosis and therapeutic options have been established for the various
tumor
grades and cellular classification.
Current recommendations, on the basis of the results of a recent phase
III
randomized trial, are that patients with glioblastoma should have maximal surgical resection followed by concurrent radiation and chemotherapy with temozolomide.
For example, allelic loss of the 1p and 19q chromosome arms predicts a dramatic improvement in response to treatment and survival for tumors histologically classified as
anaplastic
oligodendroglioma
.
Future advances for treating primary brain tumors likely will be directly related to our ability to molecularly subcategorize tumors and customize therapy based on the molecular profile within each histologic
type
and
grade
of
tumor
.
This is evident in preliminary data indicating that inactivation of the methyl guanine methyltransferase gene by hypermethylation of the promoter region specifically predicts a better
tumor
response rate to chemotherapies that alkylate DNA as their mechanism of action.
Similarly, elucidation of overly active signal transduction pathways within
tumor
cells may provide an opportunity to select the optimal therapeutic regimen composed of modulators of these pathways, analogous to restricting the use of trastuzumab to breast cancers expressing the Her-2 receptor.
Advances in treating primary
malignant
brain tumors will likely depend on collaborative clinical trials that are designed to select patients on the basis of histologic and molecular characteristics and to determine the optimal biologic dose of the best agent that can treat each specific
tumor type
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Formos Med Assoc. 2004 Jun;103(6):448-58
[
15278190.001
]
[Cites]
Neurosurgery. 1990 Jul;27(1):74-6; discussion 77
[
2377284.001
]
[Cites]
J Natl Cancer Inst. 1993 May 5;85(9):704-10
[
8478956.001
]
[Cites]
J Clin Oncol. 1998 Oct;16(10):3310-5
[
9779706.001
]
[Cites]
Cancer J. 2003 May-Jun;9(3):222-9
[
12952307.001
]
[Cites]
Semin Radiat Oncol. 2001 Apr;11(2):138-44
[
11285551.001
]
[Cites]
Cancer Metastasis Rev. 1999;18(4):451-64
[
10855788.001
]
[Cites]
Forum (Genova). 2000 Apr-Jun;10(2):108-18
[
10875973.001
]
[Cites]
AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24
[
11290467.001
]
[Cites]
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1146-52
[
9400861.001
]
[Cites]
Neuro Oncol. 1999 Jan;1(1):69-80
[
11550304.001
]
[Cites]
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
[
11814064.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
[
11020580.001
]
[Cites]
Neurosurgery. 1999 Nov;45(5):1093-104
[
10549925.001
]
[Cites]
Ann Neurol. 1983 Mar;13(3):334-6
[
6303201.001
]
[Cites]
Acta Neurochir (Wien). 2003 Jul;145(7):557-64; discussion 564
[
12910398.001
]
[Cites]
Radiology. 2002 Dec;225(3):871-9
[
12461273.001
]
[Cites]
Anticancer Res. 2001 Sep-Oct;21(5):3541-50
[
11848521.001
]
[Cites]
N Engl J Med. 2000 Nov 9;343(19):1350-4
[
11070098.001
]
[Cites]
Neurology. 2000 May 23;54(10):1886-93
[
10822423.001
]
[Cites]
Cancer Cell. 2002 Feb;1(1):31-6
[
12086885.001
]
[Cites]
Cancer Chemother Pharmacol. 1998;42(2):118-26
[
9654111.001
]
[Cites]
Neuro Oncol. 2003 Jul;5(3):153-60
[
12816721.001
]
[Cites]
Neuro Oncol. 2003 Apr;5(2):79-88
[
12672279.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10):2495-9
[
12011127.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Neurosurg. 1987 Mar;66(3):357-8
[
3819830.001
]
[Cites]
J Clin Oncol. 1999 Sep;17 (9):2762-71
[
10561351.001
]
[Cites]
Arch Neurol. 1995 Jul;52(7):717-24
[
7619029.001
]
[Cites]
J Clin Oncol. 2004 Jul 15;22(14 ):2954-63
[
15254063.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2940-9
[
12912940.001
]
[Cites]
Brain Tumor Pathol. 2000;17(2):71-8
[
11210174.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90
[
10451443.001
]
[Cites]
J Neurosurg. 2000 Jun;92(6):983-90
[
10839259.001
]
[Cites]
J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
[
11504770.001
]
[Cites]
Clin Cancer Res. 2004 Mar 15;10 (6):1871-4
[
15041700.001
]
[Cites]
Neurosurgery. 2001 Dec;49(6):1288-97; discussion 1297-8
[
11846927.001
]
[Cites]
West J Med. 1998 Feb;168(2):114-20
[
9499745.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
[
9422557.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4364-8
[
12154041.001
]
[Cites]
Am J Clin Oncol. 2004 Apr;27(2):195-204
[
15057161.001
]
[Cites]
Neuro Oncol. 2001 Jul;3(3):193-200
[
11465400.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2572-8
[
10561324.001
]
[Cites]
Thromb Haemost. 1993 Sep 1;70(3):393-6
[
8259536.001
]
[Cites]
Semin Oncol. 2004 Oct;31(5):653-8
[
15497118.001
]
[Cites]
Neuroradiology. 2004 Feb;46(2):126-9
[
14685797.001
]
[Cites]
AJNR Am J Neuroradiol. 1994 Jun;15(6):1145-8
[
8073985.001
]
[Cites]
Lancet. 2002 Mar 23;359(9311):1011-8
[
11937180.001
]
[Cites]
Cancer. 1997 Sep 1;80(5):936-41
[
9307194.001
]
[Cites]
Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20
[
12234397.001
]
[Cites]
Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
[
14765378.001
]
[Cites]
Oncogene. 2004 Mar 11;23(10):1821-8
[
15014451.001
]
[Cites]
Neuro Oncol. 2004 Jul;6(3):227-35
[
15279715.001
]
[Cites]
Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8
[
11550134.001
]
[Cites]
Expert Rev Anticancer Ther. 2004 Oct;4(5):759-82
[
15485312.001
]
[Cites]
Semin Oncol. 2004 Oct;31(5):635-44
[
15497116.001
]
[Cites]
Forum (Genova). 2000 Apr-Jun;10(2):95-104
[
10875972.001
]
[Cites]
Adv Anat Pathol. 2003 Jul;10(4):212-7
[
12826827.001
]
[Cites]
J Exp Clin Cancer Res. 1998 Dec;17(4):479-82
[
10089071.001
]
[Cites]
J Cancer Res Clin Oncol. 2003 Aug;129(8):477-84
[
12884028.001
]
[Cites]
Cancer Control. 2003 Mar-Apr;10(2):125-37
[
12712007.001
]
[Cites]
Lancet. 1995 Apr 22;345(8956):1008-12
[
7723496.001
]
[Cites]
J Neurosurg. 2001 Aug;95(2):190-8
[
11780887.001
]
(PMID = 15967092.001).
[ISSN]
1092-8480
[Journal-full-title]
Current treatment options in neurology
[ISO-abbreviation]
Curr Treat Options Neurol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
85.
Chamberlain MC, Glantz MJ:
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
J Neurooncol
; 2008 Sep;89(2):231-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted
anaplastic
oligodendroglioma
.
OBJECTIVE: A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted,
anaplastic
oligodendroglioma
(AO) with a primary objective of determining 6-month progression free survival (PFS).
CPT-11 related toxicity included diarrhea (14 patients; 4
grade
3), neutropenia (8; 4
grade
3), fatigue (12; 3
grade
3), and delayed nausea/vomiting (12; 3
grade
3).
Time to
tumor
progression ranged from 2 to 13.5 months (median: 4.5 months).
[MeSH-major]
Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives.
Neoplasm
Recurrence, Local / drug therapy.
Oligodendroglioma
/ drug therapy
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1991 May;9(5):860-4
[
1849986.001
]
[Cites]
J Clin Oncol. 1992 Sep;10(9):1379-85
[
1325539.001
]
[Cites]
J Clin Oncol. 2001 Jan 15;19(2):509-18
[
11208845.001
]
[Cites]
Neuro Oncol. 2006 Apr;8(2):189-93
[
16533878.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3389-95
[
10550132.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Neuro Oncol. 2003 Apr;5(2):79-88
[
12672279.001
]
[Cites]
Stat Med. 1991 May;10(5):749-55
[
2068428.001
]
[Cites]
J Clin Oncol. 1999 Sep;17 (9):2762-71
[
10561351.001
]
[Cites]
J Clin Oncol. 1999 May;17 (5):1516-25
[
10334539.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2940-9
[
12912940.001
]
[Cites]
J Neurooncol. 2002 Jan;56(2):183-8
[
11995820.001
]
[Cites]
Cancer. 2004 Feb 15;100(4):807-13
[
14770438.001
]
[Cites]
Cancer. 2003 May 1;97(9 Suppl):2381-6
[
12712460.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4
[
2154418.001
]
[Cites]
Ann Oncol. 2003 Dec;14(12):1727-31
[
14630676.001
]
[Cites]
Cancer. 2003 May 1;97(9 Suppl):2352-8
[
12712456.001
]
[Cites]
J Clin Oncol. 2003 Jun 15;21(12 ):2305-11
[
12805331.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
Neurology. 2004 Sep 14;63(5):904-6
[
15365146.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2572-8
[
10561324.001
]
[Cites]
Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10
[
10866344.001
]
[Cites]
Neuro Oncol. 2004 Jan;6(1):44-54
[
14769140.001
]
[Cites]
J Neurosurg. 1990 Apr;72 (4):583-8
[
2319317.001
]
[Cites]
J Natl Cancer Inst. 1959 Apr;22(4):719-48
[
13655060.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6
[
1651302.001
]
[Cites]
Lancet. 2002 Mar 23;359(9311):1011-8
[
11937180.001
]
[Cites]
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
[
17317837.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1992;23(1):3-8
[
1572829.001
]
[Cites]
Cancer. 1993 Apr 15;71(8):2585-97
[
8453582.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1992;24(4):593-7
[
1429080.001
]
[Cites]
Cancer. 2004 Mar 15;100(6):1213-20
[
15022289.001
]
[Cites]
J Clin Oncol. 2006 Mar 10;24(8):1246-52
[
16525179.001
]
[Cites]
Neuro Oncol. 2004 Jan;6(1):21-7
[
14769136.001
]
[Cites]
J Clin Oncol. 2003 Apr 15;21(8):1485-91
[
12697871.001
]
[Cites]
Lancet. 1995 Apr 22;345(8956):1008-12
[
7723496.001
]
(PMID = 18480965.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; 7GR28W0FJI / Dacarbazine; XT3Z54Z28A / Camptothecin; YF1K15M17Y / temozolomide
86.
Sega S, Horvat A, Popovic M:
Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
Clin Neurol Neurosurg
; 2006 Mar;108(3):259-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic
oligodendroglioma
and gliomatosis
type
2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
The most common cerebral neoplasms reported in MS patients were
oligodendroglioma
, astrocytoma, glioblastoma and gliomatosis.
MS can also present as a mass lesion that mimics a brain
tumor
.
To establish the correct
diagnosis
radiological follow-up and/or histological confirmation is needed.
One is a 26-year-old woman with relapsing-remitting MS and an
anaplastic
oligodendroglioma
, the other a 49-year-old woman patient with relapsing-remitting MS and gliomatosis
type
2.
Both patients were treated with interferon-beta1b and both died from the
tumor
.
The combination of a brain
tumor
and MS, and interferon-beta treatment could also be pure coincidence or an unknown side effect of treatment.
Although interferon-beta has been said to function as
a tumor
-suppressor protein, the influence of long-term treatment of MS patients on cancer development is not known.
[MeSH-major]
Brain Neoplasms / complications. Glioblastoma / complications. Multiple Sclerosis, Relapsing-Remitting / complications.
Oligodendroglioma
/ complications
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Multiple Sclerosis
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
Interferon Beta-1b
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16378678.001).
[ISSN]
0303-8467
[Journal-full-title]
Clinical neurology and neurosurgery
[ISO-abbreviation]
Clin Neurol Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 145155-23-3 / Interferon beta-1b; 77238-31-4 / Interferon-beta
87.
Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC:
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
Cancer Res
; 2006 Oct 15;66(20):9852-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with
oligodendroglioma
.
Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with
anaplastic
oligodendroglioma
.
Paraffin-embedded tissue was obtained from 21 Mayo Clinic patients and 98 patients enrolled in 2 North Central Cancer Treatment Group (NCCTG) low-
grade
glioma trials.
Upon culture, one
oligodendroglioma
contained an unbalanced 45,XX,t(1;19)(q10;p10).
Among Mayo Clinic
oligodendrogliomas
, the prevalence of fusion was 81%.
Among NCCTG patients, CEP1/19p12 fusion prevalence was 55%, 47%, and 0% among the
oligodendrogliomas
, mixed oligoastrocytomas, and astrocytomas, respectively.
The median OS for patients with low-
grade oligodendroglioma
was 9.1 years without fusion and 13.0 years with fusion (P = 0.01).
The absence of alterations was associated with a significantly shorter OS for patients
who
received higher doses of radiotherapy.
Like combined 1p/19q deletion, the 1;19 translocation is associated with superior OS and progression-free survival in low-
grade
glioma patients.
[MeSH-major]
Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 12.
Oligodendroglioma
/ genetics
[MeSH-minor]
Adolescent. Adult. Aged. Cell Cycle Proteins / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase
III
as Topic. Female. Humans. Interphase. Male. Middle Aged. Multivariate Analysis. Prognosis. Translocation, Genetic
Genetic Alliance.
consumer health - Oligodendroglioma
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17047046.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA114740; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / P01 CA85799; United States / NCI NIH HHS / CA / P50 CA108961
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / CNTRL protein, human; 0 / Cell Cycle Proteins
88.
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T:
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
J Clin Oncol
; 2006 Jun 20;24(18):2715-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed
anaplastic oligodendrogliomas
and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase
III
trial.
PURPOSE:
Anaplastic oligodendrogliomas
are more responsive to chemotherapy than high-
grade
astrocytomas.
We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with
anaplastic oligodendrogliomas
or
anaplastic
oligoastrocytomas.
In the RT arm, 82% of patients with
tumor
progression received chemotherapy.
CONCLUSION: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in
anaplastic
oligodendroglioma
.
Combined loss of 1p/19q identifies a favorable subgroup of
oligodendroglial
tumors.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy.
Oligodendroglioma
/ drug therapy
MedlinePlus Health Information.
consumer health - Brain Tumors
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Nat Clin Pract Oncol. 2007 Feb;4(2):78-9
[
17228307.001
]
[CommentIn]
J Clin Oncol. 2006 Jun 20;24(18):2689-90
[
16782906.001
]
[CommentIn]
Curr Neurol Neurosci Rep. 2007 May;7(3):189-90
[
17488583.001
]
[CommentIn]
Nat Clin Pract Neurol. 2007 Jan;3(1):14-5
[
17205067.001
]
(PMID = 16782911.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
89.
Omuro AM, Faivre S, Raymond E:
Lessons learned in the development of targeted therapy for malignant gliomas.
Mol Cancer Ther
; 2007 Jul;6(7):1909-19
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lessons learned in the development of targeted therapy for
malignant
gliomas.
The prognosis of patients with glioblastoma,
anaplastic
astrocytoma, and
anaplastic
oligodendroglioma
remains poor despite standard treatment with radiotherapy and temozolomide.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17620423.001).
[ISSN]
1535-7163
[Journal-full-title]
Molecular cancer therapeutics
[ISO-abbreviation]
Mol. Cancer Ther.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Cell Surface; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
[Number-of-references]
78
90.
Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH:
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Neuropathology
; 2007 Feb;27(1):10-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of
oligodendroglial
tumors: a clinicopathological study using fluorescence in situ hybridization.
To verify the prognostic implications of the statuses of chromosome 1p and 19q and the expressions of p53, p16 and GFAP in
oligodendrogliomas
, we investigated these parameters and correlated the results with patient outcome.
Twenty-seven cases of low-
grade oligodendroglioma
(LO) and 29 cases of
anaplastic
oligodendroglioma
(AO) were analyzed by FISH for 1p and 19q status and by immunohistochemistry for p53, p16, and GFAP expression using a tissue microarray.
p53 overexpression was observed in 17 cases (30.3%), GFAP expression in 18 cases (32.1%), and p16 loss in 40 cases (74%) of
oligodendrogliomas
.
In contrast, p53 expression was more common in
oligodendrogliomas
with an intact 19q (P= 0.029), or an intact 1p (P= 0.071).
Therefore, in
oligodendrogliomas
, the absence of the combined deletion of 1p and 19q and the aberrant expression of p53 or loss of p16 could be used as poor prognostic markers.
[MeSH-major]
Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Genes, p16 / physiology. Genes, p53 / physiology.
Oligodendroglioma
/ genetics
[MeSH-minor]
Adult. Aged. Female. Gene Expression. Gene Expression Profiling. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Prognosis. Survival Analysis. Tissue Array Analysis.
Tumor
Suppressor Protein p53 / genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17319279.001).
[ISSN]
0919-6544
[Journal-full-title]
Neuropathology : official journal of the Japanese Society of Neuropathology
[ISO-abbreviation]
Neuropathology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Australia
[Chemical-registry-number]
0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53
91.
Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM, Cher L:
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Neuro Oncol
; 2010 May;12(5):500-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase II trial of primary temozolomide in patients with
grade III oligodendroglial
brain tumors.
Glial tumors with
oligodendroglial
components are considered chemo-responsive.
Forty newly diagnosed patients (11
anaplastic oligodendrogliomas
[OD] and 29
anaplastic
oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles).
Only 18% of the patients (7 of 40) experienced treatment-related
grade
3/4 toxicities.
These data add to the growing body of data showing that primary chemotherapy may be an acceptable alternative to radiotherapy for patients with gliomas containing
oligodendroglial
histology.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives.
Oligodendroglioma
/ drug therapy
[MeSH-minor]
Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Gene Deletion. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Middle Aged.
Tumor
Suppressor Proteins / genetics. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 1997 Apr 1;79(7):1381-93
[
9083161.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):997-1003
[
15758010.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
J Neurooncol. 2006 Sep;79(2):153-7
[
16855865.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2499-503
[
16914310.001
]
[Cites]
J Clin Oncol. 2006 Oct 10;24(29):4746-53
[
16954518.001
]
[Cites]
Arch Pathol Lab Med. 2007 Feb;131(2):242-51
[
17284109.001
]
[Cites]
Nucleic Acids Res. 2007;35(6):e41
[
17289753.001
]
[Cites]
Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72
[
18272388.001
]
[Cites]
J Clin Oncol. 2008 Sep 1;26(25):4189-99
[
18757334.001
]
[Cites]
J Neurooncol. 2009 Mar;92(1):57-63
[
19011763.001
]
[Cites]
Neuro Oncol. 2009 Apr;11(2):167-75
[
18779504.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Aug;60(8):808-16
[
11487055.001
]
[Cites]
Int J Cancer. 2005 Jan 20;113(3):379-85
[
15455350.001
]
(PMID = 20406900.001).
[ISSN]
1523-5866
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
[Other-IDs]
NLM/ PMC2940620
92.
Ducray F, Idbaih A, de Reyniès A, Bièche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre O, Delattre JY, Sanson M:
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.
Mol Cancer
; 2008;7:41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anaplastic oligodendrogliomas
with 1p19q codeletion have a proneural gene expression profile.
BACKGROUND: In high
grade
gliomas, 1p19q codeletion and EGFR amplification are mutually exclusive and predictive of dramatically different outcomes.
We performed a microarray gene expression study of four high
grade
gliomas with 1p19q codeletion and nine with EGFR amplification, identified by CGH-array.
One of the most striking differences was the expression of normal brain genes by
oligodendrogliomas
with 1p19q codeletion.
Immunohistochemical study of the most differentially expressed neuronal gene, alpha-internexin, clearly differentiated the two groups of gliomas, with 1p19q codeletion gliomas showing specific staining in
tumor
cells.
CONCLUSION: These findings provide evidence for neuronal differentiation in
oligodendrogliomas
with 1p19q codeletion and support the hypothesis that the cell of origin for gliomas with 1p19q codeletion could be a bi-potential progenitor cell, able to give rise to both neurons and oligodendrocytes.
[MeSH-major]
Chromosome Deletion. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Neurons / metabolism.
Oligodendroglioma
/ genetics
[MeSH-minor]
Cluster Analysis. Genes,
Neoplasm
. Genome, Human / genetics. Humans. Immunohistochemistry. Intermediate Filament Proteins / metabolism. Neoplastic Stem Cells / pathology. Receptor, Epidermal Growth Factor / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2004 Sep 15;64(18):6503-10
[
15374961.001
]
[Cites]
Brain Pathol. 2004 Jan;14(1):34-42
[
14997935.001
]
[Cites]
J Neurosci. 1997 Jun 1;17(11):4112-20
[
9151728.001
]
[Cites]
Mol Cell Biol. 2005 Jan;25(2):685-98
[
15632069.001
]
[Cites]
Eur J Neurosci. 2005 Jan;21(1):1-14
[
15654838.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9
[
15827123.001
]
[Cites]
Genes Cells. 2005 Aug;10(8):777-83
[
16098141.001
]
[Cites]
Ann Neurol. 2005 Sep;58(3):483-7
[
16130103.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
[
16199517.001
]
[Cites]
Cancer Res. 2005 Dec 15;65(24):11335-44
[
16357140.001
]
[Cites]
Ann Neurol. 2006 May;59(5):763-79
[
16634042.001
]
[Cites]
Cancer Cell. 2006 May;9(5):391-403
[
16697959.001
]
[Cites]
Int J Cancer. 2006 Aug 15;119(4):792-800
[
16550607.001
]
[Cites]
Brain. 2006 Jul;129(Pt 7):1884-91
[
16670176.001
]
[Cites]
J Neurosci. 2006 Jul 26;26(30):7907-18
[
16870736.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9852-61
[
17047046.001
]
[Cites]
Cancer. 2006 Oct 15;107(8):1891-7
[
16986124.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17402-7
[
17090670.001
]
[Cites]
Hepatology. 2007 Jan;45(1):42-52
[
17187432.001
]
[Cites]
J Neurosci. 2007 Apr 18;27(16):4233-42
[
17442807.001
]
[Cites]
Cancer Res. 2007 May 1;67(9):4010-5
[
17483311.001
]
[Cites]
Histopathology. 2007 Jun;50(7):887-96
[
17543079.001
]
[Cites]
Int J Cancer. 2008 Apr 15;122(8):1778-86
[
18076069.001
]
[Cites]
Development. 2008 Apr;135(7):1271-81
[
18287202.001
]
[Cites]
Cancer Cell. 2006 Mar;9(3):157-73
[
16530701.001
]
[Cites]
Neuron. 2000 Dec;28(3):713-26
[
11163261.001
]
[Cites]
Cancer Res. 2001 Feb 15;61(4):1652-8
[
11245479.001
]
[Cites]
Genes Cells. 2001 Nov;6(11):977-86
[
11733035.001
]
[Cites]
Cell. 2002 Apr 5;109(1):75-86
[
11955448.001
]
[Cites]
Oncogene. 2002 Jun 6;21(25):3961-8
[
12037678.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):573-84
[
12407114.001
]
[Cites]
Nucleic Acids Res. 2003 Feb 15;31(4):e15
[
12582260.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1602-7
[
12670911.001
]
[Cites]
Nat Med. 2003 Apr;9(4):439-47
[
12627226.001
]
[Cites]
Brain Res Mol Brain Res. 1995 Mar;29(1):177-84
[
7769995.001
]
(PMID = 18492260.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Intermediate Filament Proteins; 0 / alpha-internexin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ PMC2415112
93.
Barresi V, Tuccari G, Barresi G:
NGAL immunohistochemical expression in brain primary and metastatic tumors.
Clin Neuropathol
; 2010 Sep-Oct;29(5):317-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Thus NGAL urinary detection has been proposed as a method for the early
diagnosis
of brain tumors.
In view of this, the objective of this study was to investigate whether NGAL expression differs according to brain
tumor type
or in primary vs. metastatic brain neolasias.
42 surgically resected formalin fixed and paraffin embedded neoplasias, including 15 cases of brain metastasis and 27 cases of primary central nervous system (
CNS
) tumors (11 meningiomas; 1 pilocytic astrocytoma, 2 diffuse astrocytomas, 2 oligoastrocytomas, 2
oligodendrogliomas
, 1
anaplastic
oligoastrocytoma, 7 glioblastomas, 1 ependymoma) were submitted to the immunohistochemical procedure.
NGAL staining was found in all the analyzed glioblastomas and in the
anaplastic
oligoastrocytoma.
In conclusion, our findings suggest that NGAL expression is restricted to high
grade
gliomas among primary brain tumors, and that brain metastases do not express this protein.
Considering the correlation between NGAL expression in tumors and its urinary levels, if our observations will be further validated, NGAL urinary detection might be used as an additional tool in the pre-surgical definition of brain lesions involving difficult differential
diagnosis
.
[MeSH-minor]
Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged.
Neoplasm
Metastasis. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20860895.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Acute-Phase Proteins; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
94.
Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK:
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Oncol Rep
; 2007 Jun;17(6):1359-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with
malignant
glioma.
We analyzed the clinical efficacy and toxicity of concurrent therapy as a first line modality for
malignant
glioma patients.
From 1998 to 2004, 39 patients, 22 with glioblastoma (GM), nine with
anaplastic
astrocytoma (AA), 7 with
anaplastic
oligodendroglioma
(AO) and 1 with
anaplastic
oligodendro-astrocytoma (AOA) were enrolled in this study.
Grade III
/IV hematological toxicity was reduced from 25.6 to 13% after reduction of the dose of CCNU (75 mg/m(2)).
The median interval from the completion of radiotherapy to the
diagnosis
of necrosis was 19 weeks.
Modified concurrent chemoradiotherapy may be a feasible option for treating
malignant
glioma with acceptable toxicity.
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address: